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ABSTRACT 
 Neutrophil-mediated pulmonary inflammatory conditions such as chronic obstructive 
pulmonary disease and acute lung injury/adult respiratory distress syndrome are all associated 
with high mortality rates. While they have been studied extensively, effective treatments remain 
to be found, suggesting a need to further understand the underlying mechanisms.  Nucleobindin 
2(NUCB2)/nesfatin-1 is a multifunctional protein originally found to have a role in satiety 
regulation; it has since been implicated in many other biological processes including 
inflammation. Studies have shown expression of NUCB2/nesfatin-1 in mouse lungs, and through 
animal studies, researchers have also suggested it to play an anti-inflammatory and anti-apoptotic 
role in traumatic brain injury and subarachnoid hemorrhage-induced oxidative brain damage in 
rats. Cell culture studies, on the other hand, found the addition of nesfatin-1 to chondrocytes to 
be pro-inflammatory. In addition, cultured chondrocytes and adipocytes showed that 
NUCB2/nesfatin-1 is upregulated following inflammatory stimulation. Thus far, no studies have 
characterized the expression of NUCB2/nesfatin-1 in lungs or neutrophils or its role in acute lung 
inflammation. Hence, the objective of my study was to determine the localization of 
NUCB2/nesfatin-1 in normal and inflamed lungs and neutrophils, then examine the role it plays 
following inflammatory stimulus. 
In our first study, immunohistochemistry and immune-gold electron microscopy was 
used to locate NUCB2/nesfatin-1 in normal and inflamed human and mouse lungs and 
neutrophils. We found that NUCB2/nesfatin-1 localizes in the bronchiolar epithelium, alveolar 
septa, vascular endothelium, immune cells and red blood cells of normal and inflamed human 
and mouse lungs; subcellularly, the protein is present in both the nucleus and cytoplasm. 
Furthermore, localization does not change with inflammatory status. Studies of NUCB2/nesfatin-
1 distribution within human neutrophils stimulated with LPS revealed that the protein 
accumulates within 0.5μm of the plasma membrane after 90mins of stimulation. 
NUCB2/nesfatin-1 was consistently at higher concentrations in the euchromatin compared to 
heterochromatin, and cytoplasm compared to nucleus. 
Following the localization studies, we performed mechanistic studies into the role of 
NUCB2/nesfatin-1 during LPS-induced acute lung injury by using wild type (WT) and NUCB2 
knock-out mice (NKO) mice. Acute lung injury was accessed through histological evidence of 
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injury, changes in vascular permeability and inflammatory response.  Results revealed that NKO 
lungs had higher adherent neutrophil accumulation, and inflammatory cytokine concentration 
than WT; vascular permeability was not significantly different between NKO and WT.  Further, 
examining bone marrow-derived mouse neutrophils stimulated with LPS suggested that NKO 
neutrophils may secrete less inflammatory cytokines compared to WT.   
Lastly, we determined that LPS-stimulation does not change NUCB2/nesfatin-1 mRNA 
or protein expression in mouse lungs. Protein expression of NUCB2/nesfatin-1 in mouse 
neutrophils were similarly unchanged following LPS treatment. 
Taken together, our results suggest that NUCB2/nesfatin-1 is a constitutively expressed 
protein in WT mice and plays an anti-inflammatory role during acute lung inflammation by 
inhibiting adherent neutrophil accumulation and inflammatory cytokine expression. Its presence 
in epithelial, endothelial and immune cells may enable it to inhibit neutrophil infiltration and 
adhesion, whereas its presence in neutrophilic euchromatin and its apparent ability to regulate 
inflammatory cytokine expression suggest it may play a role in regulating cytokine transcription.  
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CHAPTER 1. REVIEW OF LITERATURE 
1.1 Introduction 
The average adult breathes around 9,000 litres of air per day, continuously exposing their 
respiratory system to a large array of pathogens, and organic and inorganic particulates 
(American Medical Association, 1890). Adapted for efficient gas exchange, a human lung has 
the estimated total surface area of 24-69 square meters, making it the largest surface of the body 
to come in contact with the external environment (Hasleton et al., 1972). While the upper 
respiratory tract may come in contact with larger particulates, only those smaller than 1µm are 
typically capable of entering the alveolar space (Martin & Frevert, 2005).  
Mechanical and innate immune responses provide an important line of defense against 
exogenous materials carried in during inhalation. Mechanical defenses include the mucociliary 
system where particles sediment onto the mucus layer and are removed through the upward 
propulsive force of ciliated epithelium; the innate immune system consists of humoral 
components such as antibodies and collectins that recognize and bind to the surface of pathogens 
to promote elimination, and cellular components such as neutrophils and alveolar macrophages 
that phagocytose, release cytokines and mediate the transition from innate to adaptive immunity 
(Martin & Frevert, 2005). Innate immune responses are immediate and have relatively broad 
specificities; should they fail to resolve infection, cytokines and growth factors produced by 
macrophages and dendritic cells would subsequently facilitate the transition to adaptive 
immunity where responses are highly specific. As part of the adaptive immune response, 
regulatory, helper and cytotoxic T cells and B cells have specificities conferred by antigen-
presenting MHCI and MHCII molecules (Curtis, 2005). Their main roles include resolving of T 
cell immunity, facilitating immunological processes, destruction of infected cells, and production 
of high-affinity antibodies against antigens to facilitate their neutralization or destruction 
respectively (Curtis, 2005). Lastly, acquired immunity is conferred with the formation of 
memory T and B cells. This enables stronger and more rapid host responses in future encounters 
(Curtis, 2005). Collectively, innate and adaptive responses of the lung allow it to counteract the 
invasion of exogenous materials.    
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Amongst these defense mechanisms is acute pulmonary inflammation, a self-limited 
innate response characterized by rapid influx of inflammatory cells - predominantly neutrophils - 
through vasodilation, increased vascular permeability and recruitment of monocytes (Levy & 
Serhan, 2014). The goal of acute pulmonary inflammation is the capture and elimination of 
infectious agents, whereupon resolution, apoptotic inflammatory cells would be removed by 
macrophages to facilitate recovery by specialized proresolving mediators (Levy & Serhan, 
2014). However, in conditions such as acute lung injury (ALI) and acute respiratory distress 
syndrome (ARDS), inflammation persists and is amplified to affect the entire organ. 
Furthermore, these conditions may convert to chronic obstructive pulmonary disease (COPD) 
(Levy and Serhan, 2014). These three conditions are prominently characterized by neutrophilic 
accumulation. Although neutrophil-mediated lung inflammation is an extensively studied 
subject, these conditions remain associated with high mortality rates where no effective 
treatment is available, pointing towards the necessity to further investigate the underlying 
mechanisms of neutrophilic immune regulation (World Health Organization, 2017).  
Nucleobindin2 (NUCB2)/nesfatin-1 is a recently discovered multi-functional protein that, 
amongst its many roles, has been implicated in inflammatory responses. However, its function as 
a pro- or anti-inflammatory protein is yet to be defined. In 2014, Leivo-Korpela et al. discovered 
that human patients with COPD had levels of NUCB2/nesfatin-1 in the circulating plasma which 
correlated positively with levels of inflammatory cytokines: IL-6, IL-8 and TNF-α. Scotece et al. 
(2014) showed increased pro-inflammatory mRNA of IL-6 and MIP-1α, and IL-6 and protein 
expression of IL-8, COX-2 and MIP-1α when a murine chondrogenic cell line and primary 
human chondrocytes were incubated with 1µM nesfatin-1. In contrast, rats with subarachnoid 
haemorrhage treated intraperitoneally with 10 µg/kg nesfatin-1 showed decreased pro-
inflammatory protein expression of IL-6, IL-1β and TNF-α (Ozsavci et al., 2011). These 
conflicting results may indicate that the role of nesfatin-1 in inflammation is tissue-specific. 
My work builds upon preliminary data generated by Yadu Balachandran in our laboratory 
and aims to characterize the expression and role of NUCB2/nesfatin-1 in lung inflammation. 
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1.2 Neutrophils and Inflammation 
1.2.1 Life cycle of neutrophils 
Neutrophils are polymorphonuclear leukocytes that originate from myeloid precursors in 
the bone marrow where they reach maturation through a process termed granulopoiesis. 
Thereafter, the life cycle of mature neutrophils consists of bone marrow storage and release, 
circulation, intravascular margination, clearance and destruction (Summers et al., 2010).  
1.2.1.1 Granulopoiesis and storage 
During granulopoiesis, haematopoietic stem cells that have committed to becoming 
granulocytic progenitor cells chronologically proliferate and differentiate into myoblasts, 
promyelocytes, and myelocytes. Cell division ceases as they differentiate into metamyelocytes, 
band neutrophils and finally mature into polymorphonuclear neutrophils. After maturation, the 
bone marrow acts as a reserve where neutrophils can be stored for 4-6days and rapidly mobilized 
during inflammatory events (Rice and Teruya, 2016). Under basal conditions, only mature 
neutrophils, as opposed to its precursors, are released in significant numbers (Farlex and 
Partners, 2013).   
Neutrophil production can be stimulated by hemopoietins such as IL-3 and G-CSF (Rice 
and Teruya, 2016). In particular, G-CSF is able to reduce the average transit time through 
granulocytic compartments and expand the mitotic pool, stimulating proliferation and 
accelerating neutrophil release into circulation (Price et al., 1996). G-CSF production in 
macrophages, endothelial cells and other immune cells is up-regulated by inflammatory 
cytokines such as IL-1β and TNF-α or pathogenic toxins such as LPS (Demetri and Griffin, 
1991).   
1.2.1.2 Neutrophil circulation and recruitment 
Upon release into circulation, conservative estimates of neutrophil half-life are 
approximately 1.5 and 8 hours in mice and humans, respectively (Suratt et al., 2001; Dancey et 
al., 1976); neutrophil longevity can be extended several folds upon tissue infiltration or 
activation (Colotta et al., 1992). Neutrophils make up 50-70% of circulating leukocytes in 
humans, whereas in mice, they only make up 10-25% of the population (Mestas and Hughes, 
2004; Doeing et al., 2003). 
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Free circulating neutrophils can be recruited through activated endothelial cells where the 
increased expression of selectins on endothelial surfaces allows for tethering (Kolackowska and 
Kubes, 2013). As tethered neutrophils roll slowly along the endothelial surface, they encounter 
chemokines that result in subsequent activation (Kolackowska and Kubes, 2013). 
Conformational changes upon activation allow neutrophil integrins to initiate adhesion with 
endothelial cells; neutrophils then proceed to crawl along the chemokine gradient until they 
reach preferential sites of transmigration (Kolackowska and Kubes, 2013).  
While selectins and integrins play an important role in neutrophil recruitment, there are 
exceptions within the lung. In pulmonary circulation, capillaries - as opposed to postcapillary 
venules in other organs - are the main site of neutrophil sequestration where mechanisms can be 
selectin-independent, and CD11/CD18 integrin-independent based on activating stimulus 
(Zarbock and Ley, 2009; Looney and Bhattacharya, 2014; Doerschuk, 2001). It is proposed that 
as neutrophils (6-8 µm in diameter) pass through pulmonary capillaries (2-15 µm in diameter), 
spatial constraints, low perfusion pressure and limited cellular flexibility increases their transit 
time, facilitates sequestration and subsequent transmigration (Doerschuk, 1993; Greene K.E. and 
Parsons P.E.; Looney and Bhattacharya, 2014). 
1.2.1.3 Neutrophil margination 
Margination occurs when neutrophils transiently form intravascular pools in organs such 
as the spleen, liver and lungs (Doerschuk et al., 1987; Summers et al., 2010). In a recent study by 
Yipp et al. (2017), it was found that these neutrophils tethered, crawled or firmly adhered within 
capillaries of the lung under basal conditions. Upon stimulation with LPS, neutrophils were 
immediately triggered to the crawling stage of the recruitment cascade, showing that marginated 
neutrophils present a defense mechanism in the lung that could be activated in minutes 
independent of mononuclear phagocyte recruitment (Yipp et al., 2017). These observations built 
upon previous findings where neutrophils showed no delay in arterioles or venules but could 
spend more than 20mins to transit pulmonary capillaries to form transient margination pools 
(Lien et al., 1987). 
1.2.1.4 Neutrophil clearance and destruction 
To balance out the continuous production and release of neutrophils, a corresponding 
amount in circulation are removed and destroyed by the liver, bone marrow and spleen to 
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maintain homeostasis (Summers et al., 2010; Suratt et al., 2001). Apoptotic neutrophils display 
recognition structures that promote removal either by directing them to specific organs or 
phagocytic cells (Kolaczkowska and Kubes, 2013). There are a number of pathways for 
neutrophil cell death; depending on the pathway, neutrophils could exert a pro- or anti-
inflammatory effect on surrounding cells (Bratton and Henson, 2011). Some of common 
processes, in order from most to least pro-inflammatory, include necrosis, NETosis and 
apoptosis (Bratton and Henson, 2011). Clearance following apoptosis has little to no 
inflammatory effects as they are quickly phagocytized by macrophages; however, failure to do so 
leads to secondary necrosis and an increased inflammatory burden with cell rupture (Rydell-
Tormanen et al., 2006). 
 While it is commonly recognized that apoptotic neutrophils are cleared by macrophages 
after an inflammatory response, there is also evidence for reverse transmigration where activated 
neutrophils re-enter the vasculature (Mathias et al., 2006; Buckley et al., 2006). The biological 
function and mechanism of this phenomenon remains unclear; however, it suggests a mechanism 
through which inflammation could disseminate into other organs (Kolaczkowska and Kubes, 
2013).  
1.2.2 Neutrophil structure 
 Neutrophils are easily distinguishable from other white blood cell types by the multilobed 
(3-5 lobes) structure of their nucleus (Mescher, 2016). In circulation, they have an average 
diameter of 8 µm. Visualization methods are known to change their apparent sizes: blood smears 
tend to make neutrophils appear larger (15 µm), whereas chemical processing (e.g. during IEM, 
IFM) often reduces their size (6 µm).  
 There are 3 main types of cytoplasmic granules present in neutrophils: azurophilic 
primary granules, specific secondary granules and small storage tertiary granules. The first are 
large vesicles densely packed with proteases and anti-bacterial proteins such as lysozyme and 
myeloperoxidase (MPO). Secondary granules are smaller, but more numerous and less dense; 
they contain complement activators as well as enzymes such as collagenases. Finally, tertiary 
granules are the smallest and least dense of all 3; they contain enzymes that promote neutrophil 
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transmigration such as cathepsin, and are known to be released at the leading front of neutrophils 
during chemotaxis (Murphy, 2008).    
1.2.3 Role of neutrophils in inflammation 
The primary function of neutrophils during inflammation is the clearance of pathogens to 
resolve infection in tissues. Upon infiltrating the site of infection, neutrophils are able to 
recognize various pathogens through pattern recognition receptors (PRRs) that have affinities for 
evolutionarily conserved structures (e.g. LPS, flagellin or dsRNA) collectively referred to as 
pathogen-associated molecular patterns (PAMPs) (Mogensen, 2009). There are 3 killing 
mechanisms that neutrophils are known to employ upon such encounters: phagocytosis, 
degranulation and release of neutrophil extracellular traps (NETs).   
Phagocytosis occurs when neutrophils engulf pathogens to form phagosomes. Reactive 
oxygen species and hydrolytic enzymes are then secreted from surrounding neutrophil granules 
into the phagosomes to eliminate intracellular pathogens. Degranulation, on the other hand, 
allows neutrophils to eliminate extracellular pathogens by secreting their granules into the 
extracellular space.  
Finally, the release of NETs into the extracellular space allows highly activated 
neutrophils to immobilize pathogens through a process termed NETosis. During this process, 
neutrophilic components such as chromatin, DNA-associated proteins (e.g. histones) and various 
enzymes (e.g. MPO) facilitate the trapping, phagocytosis and direct elimination of pathogens. 
Studies have shown that NETs remain anchored to neutrophils that released them (Yipp et al., 
2012). Furthermore, neutrophils are able to continue phagocytosis and chemotaxis without lysis 
after releasing NETs (Yipp et al., 2012). Aside from bacterial infection, several conditions 
known to cause NET formation include atherosclerosis, a chronic inflammatory disease, and 
transfusion-related acute lung injury (Megens et al., 2012; Caudrillier et al., 2012).  
1.2.4 Neutrophil-mediated respiratory diseases  
While critical in defending the host against pathogen invasion, neutrophil-mediated 
inflammation also causes direct and indirect damage to lung tissues. Adverse effects induced by 
neutrophil infiltration are associated with several respiratory diseases including neutrophilic 
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asthma, acute lung injury, chronic obstructive pulmonary disease, infectious pneumonia and 
many more (Liu et al., 2017).  
Details on the role of neutrophils in various respiratory diseases is beyond the scope of 
this review, however acute lung injury/acute respiratory distress syndrome (ALI/ARDS) and 
chronic obstructive pulmonary disease (COPD) will be discussed briefly to provide 
understanding of the models used during the course of experiments. Both conditions are 
primarily neutrophil-mediated and associated with high mortality rates where only supportive 
treatment is available (World Health Organization, 2017), hence highlighting the importance of 
further exploring mediators and mechanisms behind neutrophilic inflammation.  
1.2.4.1 Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) 
 ALI/ARDS is characterized by the rapid onset of pulmonary inflammation where large 
numbers of neutrophils infiltrate the lung in a diffuse manner causing injury to both vascular 
endothelium and alveolar epithelium (Bernard et al., 1994). Cellular characteristics include 
compromised alveolar-capillary membrane integrity, excessive neutrophil infiltration, and 
release of pro-inflammatory, cytotoxic mediators (Matthay and Zimmerman, 2005). In particular, 
excessive activation of neutrophils is known to damage basement membranes and increase 
alveolar-capillary permeability through mechanical enlargement of paracellular migratory paths 
(Zemans et al., 2009). Pro-inflammatory mediators released also perpetuate damage by creating 
ulcerating lesions (Zemans et al., 2009). However, studies have also shown that ALI can develop 
in neutropenic patients, implicating the existence of alternate clinical pathways (Laufe et al., 
1986).  
The causes of this condition are heterogeneous with inherent differences in innate 
immune pathway activation, and hence also mortality-predictive cytokine concentrations (e.g. 
IL-6, IL-8, TNF-α) in BAL fluid (Park et al., 2001). Mortality risk varies according to the 
underlying clinical disorder with sepsis presenting a higher risk compared to major trauma (43% 
vs 11% mortality rate) (Eisner et al., 2001); mortality risk further increases with age where 60% 
are patients older than 85 (Rubenfeld et al., 2005). 
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1.2.4.2 Experimental model for ALI/ARDS 
Since clinical ALI/ARDS is a complex condition, there are no animal models that can 
completely recapitulate all complex components. However, several features were established by 
the American Thoracic Society to be most relevant in assessing the development of experimental 
lung injury: histological evidence of tissue injury, changes in alveolar-capillary barrier, 
inflammatory response and physiological evidence of dysfunction; at least 3 of the 4 features 
must be present to demonstrate that ALI has occurred (Matute-Bello et al., 2010). Mouse models 
of ALI, in particular, have been extensively studied, and also carry the advantage of genetic 
model availability in mice. It should be noted that apart from anatomical differences with 
humans, mice have much fewer circulating neutrophils (10-25% compared to 50-70% in 
humans), and also do not produce IL-8 (Matute-Bello et al., 2010). The lack of genetic 
variability in inbred mice, though effective in decreasing sample size required, also limits the 
range of possible outcomes (Altemeier et al., 2017).   
 Various methods are available for the induction of ALI in mice. For the purpose of this 
thesis, we have chosen to induce direct injury through intra-nasal injection of O55:B5 LPS. This 
method has been shown to allow for reproducible sterile lung inflammation to occur via Toll-like 
receptor (TLR) pathways (Takuma et al., 2005; Altemeier et al., 2017). Briefly describing the 
mechanism of action, LPS induces activation of TLR4 and TLR2 receptors which signal the 
production of pro-inflammatory cytokines through a MyD88-dependent pathway (Takuma et al., 
2005). These receptors are highly expressed in macrophages and neutrophils, and, to a lesser 
extent, in other leukocytes, endothelial and epithelial cells (Muzio et al., 2000).  
1.2.4.3 Chronic obstructive pulmonary disease 
Similar to ALI/ARDS, COPD is a pulmonary inflammatory disease characterized by 
neutrophil infiltration. Neutrophils are hypothesized to be the primary effector cells of the 
condition as patients with COPD have increased neutrophil numbers in BALF, sputum and 
intraepithelial space; neutrophil sequestration in pulmonary vasculature is similarly increased 
(Selby et al., 1991; Pilette et al., 2007; Sapey and Stockley, 2009). Neutrophil numbers 
positively correlate with degree of airflow obstruction and decline in FEV1 (volume exhaled at 
the end of the first second of forced expiration) (Donaldson et al., 2005; Pilette et al., 2007). 
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Furthermore, the resolution time of neutrophilic inflammation has been found to coincide with 
clinical recovery of COPD exacerbations (Gompertz et al., 2001).  
Studies implicate increased recruitment of neutrophils in the imbalance of proteinase and 
anti-proteinase activity observed in COPD, leading to lung proteolysis which is suggested to be 
responsible for most observed pathological features (Sapey and Stockley, 2009). The specifics on 
COPD pathology is beyond the scope of this thesis, however it is clear that further understanding 
mechanisms behind neutrophilic inflammation would aid in the development of treatment against 
COPD exacerbations.  
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1.3 Nucleobindin 2/Nesfatin-1 
1.3.1 NUCB2/Nesfatin-1 structure 
 Nucleobindin2 (NUCB2) is a 50 kDa secreted protein initially identified as a satiety 
regulatory molecule from the brain hypothalamus by Oh-I et al. in 2006. Through sequencing of 
its DNA fragment, Oh-I et al. (2006) determined that the protein is composed of 396 amino acids 
preceded by a signal peptide of 24 amino acids, with a sequence homology of >85% between 
mice, rats and humans. NUCB2 is a polyprotein, proposed to be cleaved by prohormone 
convertases (PC) into 3 fragments: nesfatin-1 (residues 1-82), nesfatin-2 (residues 85-163), and 
nesfatin-3 (residues 166-396); co-localization of nesfatin-1 with prohormone convertase 1/3 
(PC1/3) and prohormone convertase 2 (PC2) suggested that these enzymes are responsible for 
NUCB2’s post-translational processing, but this has not been further confirmed (Oh-I et al., 
2006). While NUCB2 and nesfatin-1 have been found to be biologically active, the function of 
nesfatin-2 and 3 remains unknown (Oh-I et al., 2006). With the basic amino acid rich putative 
DNA-binding domain of NUCB2 being located within nesfatin-2 and 3 segments but no nuclear 
translocation signal identified, it remains unknown whether NUCB2 localizes within the nucleus 
(Barnikol-Watanabe et al., 1994). Further, studies have shown that the leucine zipper motif- a 
three-dimensional structural motif involved with DNA-binding - found in NUCB2 cannot form 
homodimers; the possibility of heterodimer formation remains valid (Karabinos et al., 1996). 
Within the nucleobindin family, NUCB1, a 55 kDa secreted protein, is a highly similar 
homolog with >60% sequence identity with NUCB2 (Miura et al., 1992). While both proteins 
are capable of binding Ca
2+
, and in vitro DNA fragments, only NUCB1 has an identified nuclear 
localization signal (Miura et al., 1992; Barnikol-Watanabe et al., 1994; Karabinos et al., 1996). 
Unlike NUCB2, leucine zipper domains in NUCB1 causes it to form stable dimers (Miura et al., 
1992; Kapoor et al., 2010). 
1.3.2 Expression of NUCB2/Nesfatin-1 and its receptors in lungs 
 Since the characterization of NUCB2/nesfatin-1 in the rat hypothalamus (Oh-I et al., 
2006), the protein has also been identified in peripheral tissues such as the gastric mucosa, 
reproductive system, adipose tissues, and lungs (Stengel et al., 2013; Chung et al., 2013). 
NUCB2 is also a secreted protein which circulates in the plasma (Kanai et al., 1993; Barnikol-
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Watanabe et al., 1994) where its expression is differentially regulated during conditions such as 
stress, food restriction and pregnancy (Stengel et al., 2009; Garces et al., 2014; Xu et al., 2015). 
Studies in rats found that serum levels of NUCB2/nesfatin-1 increased with acute stress (Xu et 
al., 2015), and decreased after fasting for 24 hours (Stengel et al., 2009). Expression changes in 
pregnant mice depended on the day of gestation (Garces et al., 2014). From 16 days until the end 
of pregnancy, serum levels of NUCB2/nesfatin-1 was significantly decreased compared to 
control groups (Garces et al., 2014). Further, pregnant rats with a 30% food restriction showed 
decreased serum levels of NUCB2/nesfatin-1 on day 12 of gestation compared to those fed ad 
libitum (Garces et al., 2014). Other studies have suggested factors such as body weight, sex 
hormones, and type 2 diabetes mellitus to alter NUCB2/nesfatin-1 expression, however results 
have been conflicting due to variability of experimental conditions between studies (Prinz and 
Stengel, 2016).    
 In lungs, one study examined NUCB2/nesfatin-1 expression in mice during different 
developmental stages; fetal mouse lungs (15.5 days post-coitus) were found to express high 
levels of NUCB2/nesfatin-1 protein, but this expression drastically decreased in both adult males 
and females (Chung et al., 2013).  There did not seem to be a difference between genders. In a 
follow-up study, Kim et al. (2014) displayed the same Western blot data accompanied by RT-
qPCR data showing high levels of NUCB2/nesfatin-1 mRNA expression in adult mouse lungs 
relative to other peripheral organs. In contrast to protein data presented, mRNA findings also 
showed twice the NUCB2/nesfatin-1 expression in male lungs compared to female samples (Kim 
et al., 2014).  
 Little is currently known about NUCB2/nesfatin-1 receptors, hence presenting 
considerable challenge to identifying potential downstream regulatory pathways. Studies have 
suggested G-protein receptors to be likely candidates, however these receptors have yet to be 
isolated and characterized (Garcia-Marcos et al., 2011).  In an experiment to determine the 
localization of nesfatin-1 receptors in peripheral organs, Prinz et al. (2016) used 
125
I-nesfatin-1 to 
generate autoradiograph signals in rat tissue sections. Receptors were determined to be present, 
however compared to other peripheral organs, lungs displayed relatively weak labelling intensity 
(Prinz et al., 2016). 
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1.3.3 NUCB2/Nesfatin-1 in inflammation 
The widespread distribution of NUCB2/nesfatin-1 amongst various tissues also implies 
diverse functions for the protein and studies suggest its involvement in fetal development, 
glucose homeostasis, cardiovascular regulation, stress and others (Yosten and Samson, 2009; 
Garces et al., 2014, Mohan et al., 2014; Xu et al., 2015). However, very few studies have looked 
into the role of NUCB2/nesfatin-1 in inflammation.  
In one study, researchers measured the plasma levels of NUCB2/nesfatin-1 along with 
inflammatory cytokines, IL-6, IL-8, TNF-α and MMP-9, and found that levels of 
NUCB2/nesfatin-1 correlated positively with IL-6, IL-8 and TNF-α in male patients with chronic 
obstructive pulmonary disease (Leivo-Korpela et al., 2014). As macrophages and neutrophils are 
major sources of IL-6 and TNF-α, and IL-8 respectively, this study implicated their association 
with NUCB2/nesfatin-1 (Leivo-Korpela et al., 2014). Previously, it was also found that 
increasing concentrations of IL-6 and TNF-α in adipocytes differentiated from a mouse 
embryonic fibroblast cell line, 3T3-L1, increased NUCB2/nesfatin-1 protein expression 
(Ramanjaneya et al., 2010), further supporting the role of NUCB2/nesfatin-1 in inflammatory 
responses. 
In another study, Scotece et al. (2014) treated the murine chondrogenic cell line, ATDC-
5, and human primary chondrocytes from osteoarthritis patients with pro-inflammatory 
cytokines, IL-1 or TNF-α. NUCB2 mRNA and protein expression was increased as a result in 
ATDC-5 cells; increased NUCB2 protein expression was also confirmed in primary human 
chondrocytes (Scotece et al., 2014). Nesfatin-1 treatment of human primary chondrocytes 
resulted in significantly increased mRNA expression for IL-8, MIP-1α and IL-6 (Scotece et al., 
2014). Further, incubating murine chondrocytes with IL-1 and nesfatin-1 lead to increased 
mRNA and protein expression of IL-6 and MIP-1α (Scotece et al., 2014). These results from 
chondrocytes exposed to inflammatory conditions indicate that nesfatin-1 stimulates expression 
of chemotaxins (IL-8 and MIP-1α) and inflammatory cytokines (IL-6). 
While the studies above using cell cultures may suggest NUCB2/nesfatin-1 as a pro-
inflammatory cytokine, studies using animal models have suggested the contrary. In a study 
where rats with subarachnoid hemorrhage-induced oxidative brain damage were treated with 
nesfatin-1, the protein demonstrated anti-inflammatory and anti-apoptotic properties (Ozsavci et 
13 
  
al., 2011). Myeloperoxidase, a protein abundantly expressed in neutrophils, and caspase-3, an 
apoptotic protease that cleaves many key cellular proteins, were significantly reduced in 
nesfatin-1 treated samples (Ozsavci et al., 2011). This suggesting that nesfatin-1 may not have 
only inhibited neutrophil infiltration, but also apoptosis. Further support was provided by the 
demonstration of reduced lipid peroxidation within brain tissues and pro-inflammatory cytokine 
expression in plasma, both of which are parameters for inflammatory mediator release from 
neutrophils (Ozsavci et al., 2011). Lastly, when basilar arteries of nesfatin-1 treated rats were 
observed using electron microscopy, morphological changes were observed to be significantly 
reduced, demonstrating a neuroprotective effect of the protein (Ozsavci et al., 2011).  
 With similar results, a study performed on rats with traumatic brain injury found nesfatin-
1 to be anti-inflammatory and anti-apoptotic. In the group treated with 10 or 20 μg/kg nesfatin-1 
30 mins after head trauma, mRNA expression of NF-κB, TNF-α, IL-1β and IL6 decreased 
significantly (Tang et al., 2012). Caspase-3 activity and the number of apoptotic neuronal cells 
were also significantly reduced (Tang et al., 2012). 
 Taken together, cell culture studies suggest NUCB2/nesfatin-1 to be upregulated in cells 
exposed to inflammatory conditions (e.g. IL-1, TNF-α) which, in turn, upregulates expression of 
chemotaxins and other inflammatory cytokines, and perpetuates inflammatory responses. Animal 
model studies suggest NUCB2/nesfatin-1 to be an anti-inflammatory and anti-apoptotic protein, 
inhibiting neutrophil infiltration, apoptotic protein expression, and ultimately reducing tissue 
damage. Throughout the course of this thesis, we demonstrate by isolated murine and human 
neutrophils as well as murine lung injury model, the expression and potential role of 
NUCB2/nesfatin-1 in neutrophil migration and acute lung inflammation. 
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1.4 Rationale 
 Since the discovery of NUCB2/nesfatin-1 in the hypothalamus and brainstem in 2006 
(Oh-I et al.), the protein has been found in many other peripheral tissues including the lung (Kim 
et al., 2014); its role has also expanded from satiety regulation to many others including 
inflammation (Scotece et al., 2014). However, there have yet to be any studies to characterize the 
localization of its expression in lungs, or how the absence of this protein might affect lung 
inflammation. It also remains unclear whether NUCB2/nesfatin-1 exerts a pro- or anti-
inflammatory effect despite recent studies that have characterized it under various conditions 
(Leivo-Korpela et al., 2014; Scotece et al., 2014; Ozsavci et al., 2011) 
Knowing that neutrophil-mediated pulmonary inflammatory conditions such as ALI, 
ARDS and COPD are currently the leading causes of death globally due to lack of effective 
treatment (World Health Organization, 2017), characterizing NUCB2/nesfatin-1 in both lungs 
and neutrophils will lay down important groundwork to understanding the emerging role of 
NUCB2/nesfatin-1 in these conditions.  
1.4.1 Hypothesis 
1. NUCB2/nesfatin-1 is differentially expressed in normal and inflamed lungs and 
neutrophils 
2. Knock-out of NUCB2/nesfatin-1 increases lung inflammation 
3. NUCB2/nesfatin-1 mRNA and protein expression increase with LPS stimulation 
1.4.2 Objectives 
My work begins by characterizing the localization of NUCB2/nesfatin-1 in normal and 
inflamed human and mouse lungs. Then it closely examines the distribution of NUCB2/nesfatin-
1 within human neutrophils under normal and activated states. While there have been conflicting 
reports on the presence of NUCB2/nesfatin-1 expression in leukocytes (Ravussin, 2008; Stengel 
et al., 2011), its presence is confirmed in neutrophils throughout our studies. 
Afterwards, using a murine model of LPS-induced ALI, neutrophil infiltration, vascular 
permeability, and inflammatory cytokine expression in WT and NUCB2 KO mouse lungs will be 
compared to discern the potential role of NUCB2/nesfatin-1 in inflammatory regulation. 
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Peripheral blood counts are performed to identify any potential systemic changes. Lastly, mRNA 
and protein expression of NUCB2/nesfatin-1 in mouse lungs and neutrophils under normal and 
inflammatory conditions are examined in vitro, and neutrophil supernatant would also be 
assessed for differences in cytokine expression.  
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TRANSITION 
 The following chapter examines my first hypothesis that NUCB2/nesfatin-1 is 
differentially expressed in normal and inflamed lungs and neutrophils using samples from mice 
and humans. As previously mentioned, NUCB2/nesfatin-1 expression has only been confirmed 
in mouse lungs, and inflammatory stimulus has been shown to upregulate NUCB2/nesfatin-1 
mRNA and protein expression in cell culture. Our findings indicate that NUCB2/nesfatin-
1/nesfatain-3 is constitutively expressed in the nucleus and cytoplasm of pulmonary and immune 
cells. In neutrophils, the protein accumulates towards the plasma membrane following LPS-
stimulation; it is more concentrated in the cytoplasm than the nucleus of neutrophils and is more 
concentrated in the euchromatin than the heterochromatin of neutrophilic nuclei. 
 Contributions of co-authors: Yadu Balachandran performed pilot studies on which my 
localization experiments were based. Dr. Gurpreet Aulakh assisted with data analysis and 
interpretation, and provided feedback on thesis writing. Dr. Suraj Unniappan provided mice used 
in experiments, the custom NUCB2/nesfatin-1 antibody (Pacific Immunology, CA, USA) 
feedback on thesis writing, and shared much of his expertise on NUCB2/nesfatin-1. Larhonda 
Sobchishin provided technical assistance for immunoelectron microscopy. I designed and 
conducted experiments, analyzed results and wrote the thesis. Dr. Baljit Singh provided research 
directions, infrastructure, funding and feedback on thesis writing; he was involved in directing 
the collection and interpretation of immunohistochemistry and immunoelectron microscopy 
images.   
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CHAPTER 2. LOCALIZATION OF NUCLEOBINDIN2/NESFATIN-
1/NESFATIN-3 IN NORMAL AND INFLAMED HUMAN AND MOUSE 
LUNGS, AND HUMAN NEUTROPHILS 
2.1 Abstract 
 While studies have implicated NUCB2/nesfatin-1 in various inflammatory conditions - 
one in particular showing that the protein expression in human plasma positively correlated to 
expression of pro-inflammatory cytokines in patients with chronic obstructive pulmonary disease 
(COPD) - there have yet to be detailed or mechanistic studies on the role of NUCB2/nesfatin-1 in 
lung inflammation. In this study, we characterize the expression of NUCB2/nesfatin-1/nesfatin-3 
in normal and inflamed human and mouse lungs and neutrophils with light and electron 
microscopic immunocytochemistry. Light microscopy data show that the localization of 
NUCB2/nesfatin-1 in the pulmonary epithelium, alveolar septa, vascular endothelium and 
various immune cells does not change with inflammatory status while electron microscopy 
revealed constitutive localization within the nucleus and cytoplasm of the aforementioned cells. 
Immuno-gold electron microscopy showed accumulation of the protein within 0.5μm of the 
plasma membrane in human neutrophils following 90mins of 1ng/mL LPS stimulation. 
NUCB2/nesfatin-3 was also found to localize in euchromatic portions of neutrophilic nuclei at 5 
times the mean concentration compared to heterochromatin, potentially indicating a role in 
transcriptional regulation. Finally, our results indicate that NUCB2/nesfatin-3 is predominantly 
cytoplasmic as it localizes at 2 times the concentration in neutrophilic cytoplasm compared to 
nucleus. Taken together, these are the first data on detailed localization of NUCB2/nesfatin-
1/nesfatin-3 in lungs and neutrophils. 
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2.2 Introduction 
 In a study by Leivo-Korpela et al. (2014), NUCB2/nesfatin-1 was implicated in chronic 
obstructive lung disease, a neutrophil-meditated inflammatory condition that has maintained a 
high mortality rate to this day (World Health Organization, 2017). Researchers demonstrated that 
increased levels of NUCB2/nesfatin-1 in blood plasma correlated positively with IL-6, IL-8 and 
TNF-α expression (Leivo-Korpela et al., 2014). While there have been no other studies 
examining the role of NUCB2/nesfatin-1 during pulmonary inflammatory conditions, reports of 
its involvement in other inflammatory conditions such as traumatic brain injury and 
subarachnoid hemorrhage-induced brain damage where in vitro studies have demonstrated anti-
inflammatory and anti-apoptotic effects prompt us to further investigate its expression and role in 
lung inflammation (Ozsavci et al., 2011; Tang et al., 2012). 
Study of a protein’s localization within the highly compartmentalized eukaryotic system 
serves to provide information on its function, potential interaction with other molecules and 
changes during different states of activation. While the nucleotide coding sequences for 
NUCB2/nesfatin-1 were first cloned from the human lung tumor cell line, SQ-5, and its mRNA 
and protein are expressed in mouse lungs, studies have yet to determine the localization of this 
protein in mouse or human lungs (Oh-I et al., 2006; Chung et al., 2013; Kim et al., 2014). While 
one study has reported that NUCB2 mRNA was not detectable in white blood cells of rats, a 
recent study by Ravussin (2016) has shown that this does not hold true in mice and demonstrated 
mRNA expression in macrophages as well as T cells (Stengel et al., 2011). To the best of our 
knowledge, there are no detailed data on the expression or localization of NUCB2/nesfatin-1 in 
murine and human neutrophils.  
 My study aimed to fill in the gap in knowledge by first determining the cellular presence 
and location of NUCB2/nesfatin-1 in normal and inflamed human and mouse lungs through 
immunohistochemistry. We then examine the subcellular localization of NUCB2/nesfatin-1 
through immunoelectron microscopy in normal and inflamed mouse lungs. NUCB2/nesfatin-3 is 
further characterized in human neutrophils as we examine its subcellular distribution through 
immunoelectron microscopy following 0, 60, 90 and 120 mins of LPS stimulation. Finally, 
NUCB2/nesfatin-3 expression in other blood cell types, which were present as impurities during 
neutrophil isolation is briefly examined to provide hints for future research. 
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2.3 Materials and Methods 
2.3.1 Animals 
 Protocols and the use of mice in this experiment were approved by the University Animal 
Care Committee Animal Research Ethics Board of University of Saskatchewan (Protocol no.: 
20150018). C57BL/6-
Tyrc-Brd 
WT and NUCB2 knockout (NKO) male mice were generously 
donated by Dr. Suraj Unniappan. NKO mice were specifically engineered by transcriptionally 
disrupting the NUCB2 gene (Accession Number: NM_016773) through retroviral insertion of a 
trapping vector (Mohan, 2015). Genotypes of all animals used were confirmed during reverse 
transcription q-PCR of lung mRNA.  
 To study the differences between inflamed and normal mouse lungs with or without the 
presence of nucleobindin-2 (NUCB2)/nesfatin-1, WT and NKO mice, aged 3-5 months, were 
divided into LPS or PBS treatment groups (n=6 per group; 24 total). Mice were placed under 
isoflurane anaesthesia and intranasally injected with 50 µL of PBS or 1 mg/mL E. coli O55:B5 
LPS (L2880; Sigma-Aldrich, MO, USA). After 9 hours, mice were euthanized through 
anaesthesia, cardiac puncture and exsanguination. Bronchoalveolar lavage fluid (BALF) was 
collected from the lungs through 3 aspirations of 0.5 mL PBS through the trachea. 1 mL of PBS 
was then injected into the right ventricle of the heart to flush remaining blood from the lungs. 
The right main bronchus was then tied off as the left lung was perfused with 0.5 mL 4% 
paraformaldehyde/ 0.1% glutaraldehyde using a 20 cm H2O column. When perfusion was 
complete, the right lung was extracted into a cryovial and stored in liquid nitrogen; the left lung 
was fixed overnight in 1mL 4% paraformaldehyde/ 0.1% glutaraldehyde at 4°C, and processed 
for paraffin embedding the next day. 
2.3.2 Biomedical research ethics approval for human subjects 
 Sample acquisition and study of human neutrophils from healthy volunteers was 
approved by the Biomedical Research Ethics Board of University of Saskatchewan, Saskatoon, 
Canada (Protocol no.: Bio 16-170). Consent was obtained from all subjects. 
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2.3.3 Blood donation 
 Blood was collected from healthy, male volunteers between 20-40 years of age, weighing 
between 60-80 kg. A health survey was filled out by each volunteer to document that 
requirements for eligibility were met. Terms were briefly as follows: they could not participate in 
the study if they had been ill within the week, been diagnosed with HIV, hepatitis or other 
infectious diseases, had diabetes, or known pre-existing conditions that affected their 
haematology. K2 EDTA tubes (CABD367841L; BD Diagnostics, ON, Canada) were used by an 
approved technician to collect 10 mL of blood from the intravenous cannula. Samples were kept 
at room temperature and processed immediately (no longer than 30 mins) after collection. 
2.3.4 Human neutrophil extraction 
 Human neutrophils were extracted using the EasySep™ Direct Human Neutrophil 
Isolation Kit (19666; STEMCELL Technologies, BC, Canada), following the supplier’s protocol 
to process 10 mL of blood. Two cytospin slides were produced by spinning ~5x10
5
 isolated cells 
each at 500 rpm for 3 mins. Afterwards, 100-150 cells were counted on each slide and 
determined to contain ≥97% neutrophil purity before proceeding.  
2.3.5 Human neutrophil stimulation 
Isolated human neutrophils were resuspended to a concentration of 10
6
cells/mL in 
Iscove’s Modified Dulbecco’s Medium (IMDM) (ATCC) with 10% FBS. Following, 6 well 
plates were set up to contain 5x10
6
 cells per well. Cells were then stimulated with 1 ng/mL E. 
coli O55:B5 LPS (L2880; Sigma-Aldrich, MO, USA) for 0, 60, 90 and 120 mins respectively, 
and incubated at 37°C with 5% CO2. After stimulation, cells were resuspended through gentle 
pipetting, collected and washed with PBS twice before downstream processing. 
2.3.6 Tissue processing and sectioning 
 Mouse lung samples in fixative were washed for 2 hours in dH2O and then transferred 
into a tissue processor which cycles through 13 changes of reagents for 1 hour each as follows: 
70%, 80%, 95% (2x), 100% (3x) ethanol, alcohol-xylene, xylene (2x), and paraplast (3x). Upon 
completion, samples were taken out and embedded in paraffin wax. 
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Paraffin-embedded samples were trimmed until at least 5 bronchioles were visible in each 
lung section. Each slide produced thereafter would contain 4 sequentially sectioned samples, 
each 5 μm thick, to be used for immunohistochemistry and haematoxylin and eosin staining.  
2.3.7 Immunohistochemistry (IHC) 
 Mouse lung tissues used in this study were taken from the above mentioned in vivo 
experiment (n=6 per group). Human lung samples were acquired from deceased donors with 
chronic obstructive pulmonary disease (COPD) or healthy lungs (n=3 per group).  
Tissue sections were deparaffinized in xylene, rehydrated using decreasing 
concentrations of ethanol then placed into PBS. Samples were then placed in 0.5% H2O2 for 
20mins to neutralize endogenous peroxidase. After washing in PBS, antigen retrieval was 
performed by adding pepsin (2mg/mL in 0.01N HCl) to samples and incubating for 45mins. 
Samples were then washed in PBS, blocked with 5% BSA for 30mins, and incubated overnight 
in primary antibody diluted in 5% BSA. To determine the protein’s localization in normal and 
inflamed human and mouse lungs, a custom rabbit NUCB2/nesfatin-1 antibody (1mg/mL; 
Pacific Immunology, CA, USA) raised against a synthetic peptide, 
VDKTKVHNTEPVENARIEP-Cys (20 AA) was used at 1:200 and 1:150 dilutions respectively. 
The next day, samples were washed and incubated in HRP-conjugated anti-rabbit secondary 
antibody (1:200; P0448; Dako, CA, USA) for 30mins. The samples were washed in PBS and was 
developed using VECTOR VIP Peroxidase Substrate Kit (VECTOR Laboratories, ON, Canada) 
for 3-5mins depending on species. Slides were washed in dH2O and counter-stained in methyl 
green for 1min, washed in dH2O and dehydrated using increasing concentrations of ethanol 
followed by xylene. Lastly, samples were mounted and visualized under a light microscope. 
 With each set of antibodies used, the corresponding isotype and negative controls were 
performed. As a positive control, staining with polyclonal anti-human von Willebrand Factor 
(vWF) antibody (1:500; A0082; Dako, CA, USA), followed by HRP-conjugated anti-rabbit 
secondary antibody (1:200; P0448; Dako, CA, USA), was also performed in tissues of each 
species. 
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2.3.8 Immunoelectron microscopy (IEM) 
Immunoelectron microscopy (IEM) was performed on human neutrophils fixed with 2% 
paraformaldehyde/0.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 3 hours 
at 4°C. A similar processing procedure was adopted for IEM of mouse lungs. During sample 
collection, a small section of each right mouse lung was taken and fixed with 2% 
paraformaldehyde/0.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) overnight at 
4°C. The next day, tissues were washed 3 times with 0.1 M sodium cacodylate buffer and stored 
at 4°C until they could be processed for immunoelectron microscopy.  
All samples were embedded in LR White Resin, sectioned to 90 nm and mounted on 
grids. Non-specific antibody binding for human neutrophils was blocked with 3% BSA in 1x 
TBS (pH 7.9) with 0.1% Tween 20 for 30 mins; non-specific antibody binding for mouse lungs 
was blocked with 5% BSA in 1x TBS (pH 7.9) with 0.1% Tween 20 for 2 hours. Human 
neutrophil samples were then incubated in rabbit anti-NUCB2/nesfatin-3 antibody (1:20; NBP1-
87383, Novus Biologicals, ON, Canada), and mouse lung samples in rabbit anti-
NUCB2/nesfatin-1 antibody (1:20; 1mg/mL; Pacific Immunology, CA, USA) for 1 hour at RT. 
Subsequently, samples were rinsed with TBS, incubated in 15 nm gold-conjugated antibody 
(1:200; EMGAR-15; BBI International, ND, USA) for 1 hour at RT, rinsed with TBS, and 
washed in dH2O. Sample sections were visualized with a TEM-transmission electron microscope 
(Hitachi HT7700), and images were taken at 80 kV. In the imaging of human neutrophils, 10 per 
sample were randomly selected upon meeting the criteria that its nucleus was visible and plasma 
membrane was mostly intact. 
2.3.9 Statistical analysis  
 For the relative quantification of immunolabelling between compartments of different 
experimental groups using IEM, 10 neutrophils were chosen at random for each group (Control, 
LPS60, LPS90, and LPS120) with requirement that their nucleus be visible and their plasma 
membrane mostly intact. Each neutrophil was then divided into 4 regions: 0.5 µM within the 
plasma membrane (0.5PM), remainder of cytoplasm (RC), euchromatin (Eu) and 
heterochromatin (Het). The area and number of gold particles within each region were quantified 
and transformed into concentrations (Conc.) (equation 2.1). The ratios were then used for 
comparison between different cell compartments (equation 2.2, equation 2.3). 
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No. of particles/ Total area = Conc. (2.1) 
Conc.(0.5PM)/Conc.(RC) = Ratio(Cytoplasm) (2.2) 
Conc.(Euchromatin)/ Conc.(Heterochromatin) = Ratio(Nucleus) (2.3) 
Means for each group were then obtained by averaging the values for 10 neutrophils, using 
results from equation 2.2 and 2.3.  
Five biological replicates were performed. Repeated measures one-way ANOVA with 
Geisser-Greenhouse correction was used for the comparison between groups; Dunnett’s multiple 
comparisons test was used to identify groups significantly different from the control group; t-test 
was used to compare the identified groups of interest. In the case that repeated measures one-way 
ANOVA was not statistically significant, data was also analyzed for differences in 
compartmental concentrations throughout time using repeated measures two-way ANOVA 
followed by Sidak’s multiple comparisons test. Only p values ≤0.05 were considered statistically 
significant. Results are presented as Mean±SEM, and GraphPad Prism 7 (Avenida de la Playa, 
CA, USA) was used for all analysis. For a more detailed explanation of the immunolabelling 
quantification process, refer to Appendix I.  
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2.4 Results 
2.4.1 NUCB2/nesfatin-1 localizes in epithelium, endothelium, connective tissue and blood cells of 
normal and inflamed human and mouse lungs 
 First, we determined the localization of NUCB2/nesfatin-1 within normal and inflamed 
mouse and human lungs. Controls were implemented to ensure validity of our IHC protocol: 
negative controls using secondary antibody only, isotype controls corresponding to the host and 
concentration of primary antibodies, and positive controls staining von Willebrand Factor (vWF) 
protein only in endothelial cells and blood vessel endothelium of each tissue type (Figure 2.1A).  
As shown in Figure 2.1B, IHC performed with the custom NUCB2/nesfatin-1 antibody 
on normal mouse lungs shows specific staining in immune cells and red blood cells, as well as 
the alveolar septum, vascular endothelium and bronchiolar epithelium. Similarly, in inflamed 
lungs of mice (Figure 2.1C), staining can be seen in immune cells and vascular endothelium. 
Staining in red blood cells, bronchiolar epithelium, and alveolar septum of LPS-treated samples 
appeared lighter compared to its PBS-treated samples.  
Human lungs were similarly stained using the custom NUCB2/nesfatin-1 antibody. In 
normal lungs, we observed staining in all vascular endothelial layers (Figure 2.1D). In addition, 
heavy staining was present in the tunica adventitia of arteries as well as throughout the alveolar 
septum (Figure 2.1Di, ii). Staining was also observed in red blood cells, but only a few immune 
cells carried any significant staining (Figure 2.1Diii). Inflamed human lungs presented a similar 
pattern with moderate staining in all endothelial layers and red blood cells, and heavy staining in 
connective tissues, tunica adventitia and perichondrium (Figure 2.1E). Some immune cells were 
darkly stained, while others did not appear stained at all (Figure 2.1Eii). Notably, staining was 
absent in adipose tissues, hyaline cartilage and smooth muscle fibers of the tunica media (Figure 
2.1Ei, iv). 
2.4.2 NUCB2/nesfatin-1 localizes in the nucleus and cytoplasm of pulmonary cells and blood cells  
 Next, we examined normal and inflamed mouse lungs further to identify the subcellular 
localization of NUCB2/nesfatin-1. Similar to our findings with IHC staining, signals for 
NUCB2/nesfatin-1 localization were not qualitatively different between inflamed and normal 
lungs (Figure 2.2A-M). In both LPS and PBS-treated lungs, we were able to see staining in both 
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the nucleus and cytoplasm of type I and type II pneumocytes, endothelial cells, RBC (enucleate) 
and monocytes (Figure 2.2A, B, C, E, H, I, J, L). Clustering of staining could be observed in the 
monocyte nucleus (Figure 2.2E, L). Furthermore, images of an alveolar macrophage and 
neutrophil in an LPS-treated mouse lung revealed staining in the cytoplasm for both cells, with 
nuclear staining also apparent in the neutrophil (Figure 2.2F, G). Image of an eosinophil captured 
in a PBS-treated mouse lung also revealed staining in nucleus and cytoplasm (Figure 2.2M). 
Notably, much of the cytoplasmic staining resides in eosinophil granules.  
Figure 2.2N shows a negative control devoid of staining to support the validity of the 
IEM protocol used. Magnification was lowered to include a more diverse array of cells in this 
figure.  
2.4.3 NUCB2/nesfatin-3 accumulates within 0.5μm of the plasma membrane in neutrophils 
following 90mins LPS stimulation 
 To determine whether NUCB2/nesfatin-3 distributions within human neutrophils change 
with LPS treatment, NUCB2/nesfatin-3 in neutrophils stimulated for 0, 60, 90 and 120mins (Ctrl, 
LPS60, LPS90 and LPS120) were immune-gold labelled and imaged. Each neutrophil was 
divided into 4 areas (Appendix I), and the concentration of labelling (gold particles/area) was 
compared. First, we wanted to examine whether the protein concentrated towards the plasma 
membrane (PM) with LPS treatment, as supposed to the random distribution observed in control 
samples. Close proximity was defined as “within 0.5μm of PM” (0.5PM), and the remaining 
areas excluding the nucleus was defined as “remainder of cytoplasm” (RC). 
 When the ratios of 0.5PM/RC were compared in a repeated measures one-way ANOVA, 
results revealed the groups were significantly different (p=0.010). Post-hoc analysis using the 
Dunnett’s multiple comparisons test determined that neutrophils stimulated for 90mins had a 
statistically significant difference in 0.5PM/RC gold particle ratio compared to control samples, 
presenting a mean NUCB2/nesfatin-3 concentration 1.8 times higher at 0.5PM than RC; the 
0.5PM/RC ratio in LPS90 samples were 1.6 times that of control samples (p=0.017; Figure2.3A). 
 To determine which compartment’s change in mean NUCB2/nesfatin-3 concentration 
effected this result, we performed repeated measures one-way ANOVA on 0.5PM and RC 
compartments separately; neither were statistically significant (p=0.626 and 0.187 respectively). 
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However, we note that NUCB2/nesfatin-3 concentrations remained relatively constant in the 
0.5PM compartment, while the Ctrl group in the RC compartment had 1.8 times the mean 
NUCB2/nesfatin-3 concentration of LPS90. The observation suggests NUCB2/nesfatin-3 is 
depleted from the RC compartment after 90 mins of LPS stimulation while its concentration in 
the 0.5PM compartment does not change. 
2.4.4 NUCB2/nesfatin-3 is constitutively more concentrated in euchromatin than heterochromatin 
portions of neutrophilic nuclei 
 Next, we examined whether the distribution of NUCB2/nesfatin-3 within neutrophilic 
nuclei changed with LPS treatment. The lighter portion of nuclei was defined as euchromatin 
(Eu), and the darker portion heterochromatin (Het) (Appendix I, Figure I.III). Repeated measures 
one-way ANOVA revealed that groups did not significantly differ (p=0.265; Figure 2.4A). 
However, results did show a consistent 5 times higher mean NUCB2/nesfatin-3 concentration in 
Eu compared to Het throughout LPS stimulation time points.  
To determine whether this observation was statistically significant, we performed a 
repeated measures two-way ANOVA, followed by Sidak’s multiple comparisons test. Results 
from the two-way ANOVA indicated that mean NUCB2/nesfatin-3 concentrations did not 
significantly differ throughout time (p=0.467), but were significantly different between 
compartments (p=0.001). Finally, Sidak’s multiple comparisons test used to compare mean 
NUCB2/nesfatin-3 concentrations between Eu and Het portions across all time points revealed 
that the 5 times difference observed was statistically significant (p<0.003; Figure 2.4B). 
2.4.5 NUCB2/nesfatin-3 is consistently more concentrated in neutrophil cytoplasm than nuclei  
 In our last study of NUCB2/nesfatin-3 distribution with LPS stimulation, we determined 
whether the protein accumulated in nuclei or cytoplasm differently throughout (Appendix I, 
Figure I.III). Comparing mean labelling concentrations in the cytoplasm (Cyto) and nuclei (Nu), 
repeated measures one-way ANOVA revealed no significant difference between groups 
(p=0.276; Figure 2.5A). However, results showed a consistent 2 times higher mean 
NUCB2/nesfatin-3 concentration in Cyto compared to Nu. To determine whether this 
observation was statistically significant, a repeated measures two-way ANOVA was performed 
comparing the two variables: duration of LPS stimulation, and compartment (Cyto or Nu).  
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Results revealed that while the duration of LPS stimulation was not a significant factor in 
differences of NUCB2/nesfatin-3 concentration (p=0.401), compartmental differences was 
(p=0.001). Sidak’s multiple comparisons test revealed that the observed 2 times higher mean 
NUCB2/nesfatin-1 concentration in Cyto compared to Nu was significant across all time points 
(p<0.003; Figure2.5B).  
2.4.6 NUCB2/nesfatin-3 immunogold staining is high in neutrophils and red blood cells, but low in 
eosinophils, lymphocytes and monocytes 
 During the course of imaging human neutrophils for NUCB2/nesfatin-3 distribution 
studies, we also came across other immune cells due to impurities from neutrophil isolation. 
Figure2.6 shows immune cells of LPS-treated samples, imaged to establish an idea of 
NUCB2/nesfatin-3 abundance in other blood cell types, complimentary to information of 
NUCB2/nesfatin-1 localization in mouse lung. 
Observed throughout the NUCB2/nesfatin-3 distribution studies of human neutrophils, 
high levels of staining are present within the nucleus and cytoplasm (Figure2.6A). Similarly, red 
blood cells displayed high levels of labelling with the additional presence of clusters throughout 
(Figure2.6B). In contrast, NUCB2/nesfatin-3 staining was scarce in eosinophils and 
lymphocytes, each cell showing no more than 5 immunogold particle (Figure2.6C, D). Finally, 
we observe the presence of NUCB2/nesfatin-3 in the nucleus and cytoplasm of monocytes albeit 
in substantially lower quantities than neutrophils (Figure2.6E). 
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Figure 2.1A: Immunohistochemistry controls.  
Lung sections from human and mouse were stained with only secondary antibody (negative control), IgG 
rabbit antibody (isotype control) and vWF (positive control). Negative and isotype controls were devoid 
of antibody staining, while vWF strongly stained vascular endothelium (arrows), but not epithelium.  
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Figure 2.1B: Immunohistochemistry of NUCB2/nesfatin-1 staining in WT PBS-treated mouse lung.  
Images are representative of NUCB2/nesfatin-1 staining pattern in WT PBS-treated mouse lungs. Image 
in 20X magnification (above) presents an overview; image in 60X magnification (below) shows specific 
staining in RBC (black arrow), immune cells (red arrows), alveolar septum, vascular endothelium and 
bronchiolar epithelium. AS: Alveolar space; V: vein; B: bronchiole. 
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Figure 2.1C: Immunohistochemistry of NUCB2/nesfatin-1 staining in WT LPS-treated mouse lung.  
Images are representative of NUCB2/nesfatin-1 staining pattern in WT LPS-treated mouse lungs. Image 
in 20X magnification (above) presents an overview; image in 60X magnification (below) shows specific 
staining in RBC (black arrow), immune cells (red arrows), alveolar septum, vascular endothelium and 
bronchiolar epithelium. AS: Alveolar space; V: vein; B: bronchiole. 
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Figure 2.1D: Immunohistochemistry of NUCB2/nesfatin-1 staining in normal human lungs.  
Images are representative of NUCB2/nesfatin-1 staining pattern in normal human lungs. Images in 20X 
magnification (left) present an overview; images in 60X magnification (right) show specific staining in 
RBCs (black arrows), immune cells (red arrows), alveolar septum, endothelium, and artery tunica 
adventitia. A: Artery; C: capillary; V: vein; AS: Alveolar space. 
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Figure 2.1E: Immunohistochemistry of NUCB2/nesfatin-1 staining in inflamed human lungs. 
 Images are representative of NUCB2/nesfatin-1 staining pattern in inflamed human lungs. Images in 
10X/20X magnification (left) present an overview; images in 60X magnification (right) show specific 
staining in RBCs (black arrows), immune cells (red arrows), endothelium, perichondrium, alveolar 
septum, ciliated epithelium and artery tunica adventitia. P: Perichondrium; AT: adipose tissue; HC: 
hyaline cartilage; A: Artery; C: capillary; V: vein; AS: Alveolar space; AW: Airway. 
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Figure 2.2A: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in LPS-treated mouse lung.  
Type I pneumocyte of a mouse lung treated with LPS for 9 hours shows NUCB2/nesfatin-1 (arrows) 
(n=6). Nu: Nucleus; AS: alveolar space. Original magnification: X15,000. 
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Figure 2.2B: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in LPS-treated mouse lung.  
Type II pneumocyte of a mouse lung treated with LPS for 9 hours shows NUCB2/nesfatin-1 (arrows) 
(n=6). Nu: Nucleus; L: lamellar bodies; M: microvilli; AS: alveolar space; I: type I pneumocyte. Original 
magnification: X15,000. 
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Figure 2.2C: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in LPS-treated mouse lung.  
Endothelial cell and red blood cells in alveoli of a mouse lung treated with LPS for 9 hours shows 
NUCB2/nesfatin-1 (arrows) (n=6). Nu: Nucleus; RBC: red blood cell; CL: capillary lumen; En: 
endothelium; BL: basal lamina; Epi: epithelium; AS: alveolar space. Original magnification: X15,000. 
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Figure 2.2D: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in LPS-treated mouse lung.  
Red blood cell and alveolar capillary of a mouse lung treated with LPS for 9 hours shows 
NUCB2/nesfatin-1 (arrows) (n=6). RBC: Red blood cell; CL: capillary lumen; En: endothelium; BL: 
basal lamina; Epi: epithelium; AS: alveolar space. Original magnification: X15,000. 
  
RBC 
CL 
Epi 
Epi 
BL 
En 
AS 
AS 
38 
  
 
Figure 2.2E: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in LPS-treated mouse lung.  
Monocyte and alveolar capillary of a mouse lung treated with LPS for 9 hours shows NUCB2/nesfatin-1 
(arrows) with staining clustered within monocyte (red box) (n=6). Nu: Nucleus; En: endothelium; BL: 
basal lamina; Epi: epithelium; AS: alveolar space; RBC: red blood cell. Original magnification: X15,000. 
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Figure 2.2F: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in LPS-treated mouse lung.  
Macrophage in a mouse lung treated with LPS for 9 hours shows NUCB2/nesfatin-1 (arrows) (n=6). N: 
Neutrophil; Epi: epithelial cell; AS: alveolar space. Original magnification: X15,000. 
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Figure 2.2G: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in LPS-treated mouse lung.  
Neutrophil in a mouse lung treated with LPS for 9 hours shows NUCB2/nesfatin-1 (arrows) (n=6). Nu: 
Nuclear; M: macrophage; RBC: red blood cell; AS: alveolar space. Original magnification: X15,000. 
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Figure 2.2H: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in PBS-treated mouse lung.  
Type I pneumocyte of a mouse lung treated with PBS for 9 hours shows NUCB2/nesfatin-1 (arrows) 
(n=6). Nu: Nucleus; AS: alveolar space; RF: reticular fibres. Original magnification: X15,000. 
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Figure 2.2I: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in PBS-treated mouse lung.  
Type II pneumocyte of a mouse lung treated with PBS for 9 hours shows NUCB2/nesfatin-1 (arrows) 
(n=6). Nu: Nucleus; L: lamellar bodies; M: microvilli; AS: alveolar space. Original magnification: 
X15,000. 
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Figure 2.2J: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in PBS-treated mouse lung.  
Endothelial cell of a mouse lung treated with PBS for 9 hours shows NUCB2/nesfatin-1 (arrows) (n=6). 
Nu: Nucleus; RBC: red blood cell; CL: capillary lumen; En: endothelium; BL: basal lamina; Epi: 
epithelium; AS: alveolar space. Original magnification: X15,000. 
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Figure 2.2K: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in PBS-treated mouse lung.  
Red blood cell and alveolar capillary of a mouse lung treated with PBS for 9 hours shows 
NUCB2/nesfatin-1 (arrows) (n=6). RBC: Red blood cell; CL: capillary lumen; En: endothelium; BL: 
basal lamina; Epi: epithelium; AS: alveolar space. Original magnification: X15,000. 
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Figure 2.2L: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in PBS-treated mouse lung. 
 Monocyte and alveolar capillary of a mouse lung treated with PBS for 9 hours shows NUCB2/nesfatin-1 
(arrows) with staining clustered within monocyte (red box) (n=6). Nu: Nucleus; En: endothelium; BL: 
basal lamina; Epi: epithelium; RBC: red blood cell; AS: alveolar space. Original magnification: X15,000. 
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Figure 2.2M: Immuno-gold electron microscopy for NUCB2/nesfatin-1 in PBS-treated mouse lung.  
Eosinophil in a mouse lung simulated by PBS for 9 hours shows NUCB2/nesfatin-1 (arrows) (n=6). Nu: 
Nucleus; EG: eosinophil granules; RBC: red blood cell; En: endothelium; BL: basal lamina; Epi: 
epithelium; AS: alveolar space. Original magnification: X15,000. 
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Figure 2.2N: Negative control for immuno-gold electron microscopy of mouse lung.  
Sample is devoid of gold particle staining. Nu: Nucleus; RBC: red blood cell; Mono: monocyte; En: 
endothelium; Epi: epithelium; AS: alveolar space. Original magnification: X10,000. 
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Figure 2.3: 0.5PM/RC NUCB2/nesfatin-3 distribution ratio in human neutrophils on LPS challenge.  
NUCB2/nesfatin-3 was labelled with immunogold particles and quantified. (A) Distribution ratios of 
NUCB2/nesfatin-3 after human neutrophils were challenged for 0, 60, 90, and 120mins with LPS 
(1ng/mL) were obtained by dividing the concentration of immunogold particles within 0.5µm of plasma 
membrane (0.5PM) by the concentration of immunogold particles in the remainder of the cytosol (RC). 
Repeated measures one-way ANOVA revealed statistical difference between groups (p=0.010); Dunnett’s 
multiple comparisons test determined that Ctrl and LPS90 were statistically different (p=0.017). (B, C) 
One-way ANOVA on NUCB2/nesfatin-3 concentrations in the 0.5PM or RC compartment alone revealed 
no statistical difference throughout time (p=0.626 and 0.187 respectively). Notably, however, when a 
t-test comparing Ctrl and LPS90 in the RC compartment was performed, results were close to achieving 
statistical significance (p=0.073). (**p≤0.01 compared to control; data shown as mean ± SEM; n=5). 
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Figure 2.4: Eu/Het NUCB2/nesfatin-3 distribution ratio in human neutrophils on LPS challenge.  
NUCB2/nesfatin-3 was labelled with immunogold particles and quantified. (A) Distribution ratios of 
NUCB2/nesfatin-3 after human neutrophils were challenged for 0, 60, 90, and 120mins with LPS 
(1ng/mL) were obtained by dividing the concentration of immunogold particles within the euchromatin 
portion of nuclei (Eu) by the concentration of immunogold particles in the heterochromatin portion of 
nuclei (Het). Repeated measures one-way ANOVA revealed no statistical significant difference between 
groups (p=0.265). (B) Following, immunogold labelling of Eu and Het compartments throughout time 
was compared. Repeated measures two-way ANOVA reveals significant difference between 
compartments (p=0.001), but no difference in each compartment across time (p=0.467). Sidak’s multiple 
comparisons test reveals that the significant difference between compartments was true across all time 
points (p<0.003). (*p<0.003; Data shown as mean ± SEM; n=5). 
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Figure 2.5: Cyto/Nu NUCB2/nesfatin-3 distribution ratio in human neutrophils on LPS challenge.  
NUCB2/nesfatin-3 was labelled with immunogold particles and quantified. (A) Distribution ratios of 
NUCB2/nesfatin-3 after human neutrophils were challenged for 0, 60, 90, and 120mins with LPS 
(1ng/mL) were obtained by dividing the concentration of immunogold particles within the cytoplasm 
(Cyto) by the concentration of immunogold particles in nuclei (Nu). Repeated measure one-way ANOVA 
revealed no statistical significant difference between groups (p=0.276). (B) Following, immunogold 
labelling of Cyto and Nu compartments throughout time was compared. Repeated measures two-way 
ANOVA reveals significant difference between compartments (p=0.001), but no difference in each 
compartment across time (p=0.401). Sidak’s multiple comparisons test reveals that the significant 
difference between compartments was true for all time points (*p<0.003; Data shown as mean ± SEM; 
n=5). 
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Figure 2.6: Immuno-gold electron microscopy for NUCB2/nesfatin-3 in LPS-treated human 
immune cells.  
Immune cells present as impurities in human neutrophil samples were imaged. Along with (A) 
neutrophils, (B) red blood cells, (C) eosinophils, (D) lymphocytes, and (E) monocytes, identified from 
LPS-stimulated samples, were stained for NUCB2/nesfatin-3 (arrows). Original magnification: X15,000. 
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2.5 Discussion 
NUCB2/nesfatin-1 is expressed in adult mouse lungs, albeit at lower levels compared to 
the fetal stage (Chung et al., 2013; Kim et al., 2014). In addition, mRNA expression in female 
mouse lungs has been shown to be significantly lower than male (Kim et al., 2014). Knowing 
that the protein is also expressed in reproductive organs, and fluctuates in serum of rat mothers 
during pregnancy, there is also a chance its expression would be affected by the estrous cycle 
(Kim et al., 2014; Garces et al., 2014). With these considerations in mind, all samples collected, 
with the exception of human lungs, are from males. Mice used are classified as mature adults, 
age varying from 3-5months, with a fully developed immune system not yet affected by 
senescence (The Jackson Laboratory, 2015). The custom rabbit NUCB2/nesfatin-1 antibody 
(1mg/mL; Pacific Immunology, CA, USA) used on mouse and human lungs detects both 
NUCB2 and, its post-translational product, nesfatin-1; our results do not distinguish between the 
two and refer to the proteins collectively as NUCB2/nesfatin-1. Similarly, the polyclonal rabbit 
NUCB2/nesfatin-3 antibody (NBP1-87383, Novus Biologicals, ON, Canada) used on human 
neutrophils detects NUCB2 and nesfatin-3. Nesfatin-1 (~10kDa) and nesfatin-3 (~28kDa) were 
not detected during Western blot analysis of mouse lung homogenates and human neutrophil 
lysates respectively, therefore signals from immunocytochemistry are expected to predominantly 
arise from full length NUCB2 (~50kDa) (Appendix II, Figure II.III and II.IVA). Nonetheless, 
NUCB2/nesfatin-1, NUCB2/nesfatin-3, or NUCB2/nesfatin-1/nesfatin-3 will be used during the 
discussion of our findings. A detailed discussion on antibodies used can be found in Appendix II. 
 While studies have shown NUCB2/nesfatin-1 expression to increase following 
inflammatory stimulus (Ramanjaneya et al., 2010; Leivo-Korpela et al., 2014; Scotece et al., 
2014), no significant quantitative or qualitative differences were observed in immunohistological 
staining of normal and inflamed mouse or human lungs. In both normal and inflamed mouse 
lungs, heavy NUCB2/nesfatin-1 staining was notably present in immune cells, while red blood 
cells, alveolar septum, vascular endothelium and bronchiole epithelium were stained to a lesser 
degree. In both normal and inflamed human lungs, immune cells displayed varying degrees of 
staining, from heavy to absent. Since we cannot definitively differentiate between immune cell 
types with these images, it is possible these immune cells belong to different populations. 
Another possibility for this variability may be the age of sample blocks which have been stored 
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for at least 5 years, resulting in reduced signal for proteins (Nuovo et al., 2013). Similar to 
mouse lungs, human lungs also displayed staining in red blood cells, alveolar septum, vascular 
endothelium and bronchiole epithelium. In addition, we observed that staining was completely 
absent in adipose tissues and hyaline cartilage. Where the tunica adventitia of arteries (composed 
mostly of connective tissue and fibroblasts) carried substantial staining, smooth muscle fibers of 
the tunica media did not stain.   
 Similar to our immunohistological results, immunoelectron microscopy also revealed 
little qualitative difference in staining between normal and inflamed mouse lungs. 
NUCB2/nesfatin-1 was present in the nucleus and cytoplasm of epithelial and endothelial cells as 
well as immune cells such as eosinophils, neutrophils and monocytes. The protein was not 
confined to secretory granules; however, a notable amount was observed within eosinophil 
granules. Immunoelectron microscopy images of various human blood cell types build upon 
observations from human lung immunohistochemistry: NUCB2/nesfatin-1/nesfatin-3 is present 
in different quantities amongst immune cells. Neutrophils and red bleed cells carried the most 
staining, monocytes showed substantially less, and staining was scarce in eosinophils and 
lymphocytes. We observed that staining was present in the nucleus and cytoplasm of neutrophils, 
lymphocytes and monocytes whereas staining was only observed in the cytoplasm but not the 
nucleus of eosinophils. In contrast to mouse eosinophils, NUCB2/nesfatin-1/nesfatin-3 did not 
appear to accumulate in human eosinophilic granules. 
 Quantitative analysis of gold particle distribution within human neutrophils stimulated for 
0, 60, 90 and 120mins with 1ng/mL LPS revealed that NUCB2/nesfatin-3 accumulated within 
0.5μm of the plasma membrane after 90mins of LPS treatment. The protein was notably depleted 
from the central portions of cytosol while concentrations remained unchanged close to the 
plasma membrane. This change may indicate an interaction of NUCB2/nesfatin-3 with proteins 
located at the cytoplasmic periphery, or proteins that migrate towards the plasma membrane 
upon neutrophil activation. Future studies may use co-immunoprecipitation after LPS stimulation 
to explore such potential interactions. Further, we found that NUCB2/nesfatin-3 was consistently 
5 times as concentrated in the euchromatin relative to the heterochromatin portion of the nucleus. 
Considering the lack of an identifiable nuclear translocation signal (Barnikol-Watanabe et al., 
1994), the protein may have been trafficked into the nucleus through associating with another 
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protein. Its locational preference for the euchromatin, which contains highly decondensed 
chromatin often under active transcription, may also indicate a role in transcriptional regulation. 
Comparing NUCB2/nesfatin-3 concentrations between the cytoplasm and nucleus revealed a 
consistent 2 times higher mean concentration in the cytoplasm, indicating that the majority of the 
protein was cytoplasmic despite its ability to enter the nucleus. To further investigate the 
potential role of NUCB2/nesfatin-1 in transcription, a pilot experiment was conducted in attempt 
to identify DNA sequences that NUCB2/nesfatin-1 interacted with through chromatin 
immunoprecipitation sequencing; although ultimately unsuccessful, details of progress made can 
be found in Appendix III. 
 It is worth noting that during the course of immunohistochemistry studies, we attempted 
to create additional controls such as knockout and antigen preabsorption controls without success 
(Appendix II). Although Western blot results using lung and neutrophil homogenates indicated 
that all antibodies used have sufficient immunoreactivity towards NUCB2, it is likely that cross-
reactivity is present (Appendix II). Considering the limited options currently commercially 
available, that our custom antibody has an advantage over others in detecting NUCB2/nesfatin-1 
without cross-reaction with its homolog, NUCB1, and that our NUCB2/nesfatin-3 antibody is the 
only one tested to achieve an amount of immunogold staining in IEM suitable for quantitative 
comparisons, our current results demonstrate the extent of localization information that could be 
obtained through immunological methods. Pilot experiments using immunofluorescence 
microscopy were conducted on mouse neutrophils for further NUCB2/nesfatin-1 localization 
results. Although findings were concurrent with our aforementioned results, negative controls 
showed non-specific staining and hence failed to validate the protocol used (Appendix III). 
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TRANSITION 
 In this study, we expand from the knowledge of NUCB2/nesfatin-1/nesfatin-3 
localization to what role the protein might play in normal and inflamed lungs and neutrophils. 
Although studies have shown NUCB2/nesfatin-1 to be expressed in lungs and involved in 
inflammatory responses, this following study is the first to describe its role in acute lung injury.   
Through the use of WT and NUCB2 KO mice, we examine our hypotheses that absence 
of NUCB2/nesfatin-1 increases lung inflammation, and NUCB2/nesfatin-1 mRNA and protein 
expression increase with LPS stimulation. Our findings reveal increased adherent neutrophil 
accumulation and inflammatory cytokine expression with the loss of NUCB2/nesfatin-1. In 
mouse neutrophils, the loss of NUCB2/nesfatin-1 resulted in decreased inflammatory cytokine 
expression. Lastly, NUCB2/nesfatin-1 mRNA and protein expression in lungs and neutrophils 
did not appear to change with inflammatory status. The following chapter details my research on 
the role of NUCB2/nesfatin-1 in response to inflammatory stimulus in mouse lungs and 
neutrophils. 
 Contributions of co-authors: Dr. Aulakh provided technical support, helped with 
conducting experiments, data analysis and interpretation, and provided feedback on thesis 
writing. Dr. Unniappan provided mice used in experiments, feedback on thesis writing, and 
shared his expertise on NUCB2/nesfatin-1. I designed and conducted experiments, analyzed 
results and compiled the thesis. Dr. Singh provided research directions, infrastructure, funding 
and feedback on thesis writing.   
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CHAPTER 3. ROLE OF NUCLEOBINDIN2/NESFATIN-1 IN 
INFLAMMATORY RESPONSE OF MOUSE LUNGS AND NEUTROPHILS 
3.1 Abstract 
 Cell culture studies of chondrocytes and adipocytes have shown increased 
NUCB2/nesfatin-1 expression following inflammatory stimulus. Moreover nesfatin-1 treatment 
was found to increase expression of pro-inflammatory cytokines chondrocytes. In contrast, 
animal studies with rat models of subarachnoid hemorrhage-induced oxidative brain damage and 
traumatic brain injury suggest that nesfatin-1 plays in anti-inflammatory and anti-apoptotic role. 
Since no studies thus far have looked into the role of NUCB2/nesfatin-1 in lung inflammation, 
our project would be the first to use WT and NUCB2 KO mice to examine its role in LPS-
induced acute lung injury. In addition, we also explore the response of WT and NUCB2 KO 
bone marrow isolated mouse neutrophils to LPS treatment. Our findings suggest that the absence 
of NUCB2/nesfatin-1 significantly increases accumulation of adherent neutrophils by 
approximately 3 times compared to WT within LPS-treated lungs. Integrating this with 
observations from both BALF and neutrophil cytokine expression, we propose that although 
neutrophils lacking NUCB2/nesfatin-1 individually secrete less pro-inflammatory cytokines 
compared to stimulated WT cells, the result of knocking out NUCB2/nesfatin-1 is net pro-
inflammatory. No change was found in NUCB2/nesfatin-1 mRNA or protein expression 
comparing WT LPS and PBS-treated samples. Taken together, our results show that 
NUCB2/nesfatin-1 is constitutively expressed in mouse lungs and neutrophils, and demonstrates 
anti-inflammatory properties in mouse lungs during acute lung injury by inhibiting adherent 
neutrophil accumulation and inflammatory cytokine expression. 
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3.2 Introduction 
Acute lung injury/ acute respiratory distress syndrome (ALI/ARDS) are conditions of 
acute respiratory failure associated with high morbidity and mortality rates (World Health 
Organization, 2017). Etiology of ALI/ARDS include sepsis, lung infections, trauma, blood 
transfusions and more (Flierl et al., 2006). Sepsis, in particular, is a predisposing clinical factor 
with one of the highest incidence of developing ARDS (Rubenfeld et al., 2005). Cellular 
characteristics of ALI/ARDS generally include loss of alveolar-capillary barrier integrity, 
increased neutrophil accumulation, and pro-inflammatory mediators (Matthay and Zimmerman, 
2005). In one study, researchers identified elevated BAL and plasma levels of IL-6, IL-8 and 
TNF-α as strong predictors of mortality (Park et al., 2001; Parsons et al., 2005). Neutrophils play 
an especially important role in ALI/ARDS as they tend to damage the alveolar-capillary barrier 
through mechanical means as well as release of pro-inflammatory and pro-apoptotic mediators 
(Zemans et al., 2009). Should the inflammation fail to resolve, progression of injury may lead to 
additional complications including a transition into chronic obstructive pulmonary disease and 
multiple organ failure (Matthay and Zimmerman, 2005). Due to various conditions that may 
accompany ALI/ARDS, treatment tends to be challenging.  
Following the previous chapter where results showed that NUCB2/nesfatin-1 localizes in 
pneumocytes and various immune cells throughout mouse and human lungs without exhibiting 
spatial changes between PBS or LPS treatment, we aim to determine the importance of its 
presence during lung inflammation. Previous in vitro experiments involving animal models have 
demonstrated an anti-inflammatory and anti-apoptotic effect of nesfatin-1 in subarachnoid 
hemorrhage-induced brain damage and the traumatic rat brain (Ozsavci et al., 2011; Tang et al., 
2012). In these studies, administration of nesfatin-1 not only decreased levels of pro-
inflammatory cytokines such as TNF-α, IL-1β and IL-6, oxidative enzymatic activity associated 
with neutrophil activation and apoptosis also decreased (Ozsavci et al., 2011; Tang et al., 2012). 
Lastly, results demonstrated a protective effect of nesfatin-1 treatment on tissues such as basilar 
arteries and neurons that would otherwise have suffered oxidative damage (Ozsavci et al., 2011; 
Tang et al., 2012). A previous study of NUCB2/nesfatin-1 in chronic obstructive pulmonary 
disease (COPD) has also shown a positive correlation between NUCB2/nesfatin-1 levels and 
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systemic inflammation (Leivo-Korpela et al., 2014). However, no study thus far has been done to 
examine the role of NUCB2/nesfatin-1 in acute lung inflammation. 
Previously, we have mentioned that studies done in cell culture demonstrated an increase 
in NUCB2/nesfatin-1 mRNA and protein expression upon stimulation with pro-inflammatory 
cytokines such as IL-1, IL-6 and TNF-α (Ramanjaneya et al., 2010; Scotece et al., 2014). 
Furthermore, findings from one study seemed contradictory to animal model studies, showing 
increased pro-inflammatory cytokine expression following nesfatin-1 treatment in a murine 
chondrogenic cell line and human primary chondrocytes exposed to inflammatory conditions 
(Scotece et al., 2014). These pro-inflammatory cytokines included IL-6, IL-8 and MIP-1α 
(Scotece et al., 2014). While neutrophils play central roles in inflammation including acute 
inflammation in the lungs, there are currently no data showing the effect of NUCB2/nesfatin-1 
on neutrophil cytokine expression. 
To examine the role of NUCB2/nesfatin-1 in acute lung inflammation, we used a well-
established mouse model of LPS-induced ALI. WT and NUCB2 KO (NKO) mice were treated 
with LPS and their lungs were assessed for inflammatory response. Considering the central role 
of neutrophils in ALI, we also evaluated cytokine expression in bone marrow derived neutrophils 
from WT and NKO mice. Lastly, our studies evaluate whether inflammatory stimulus causes any 
NUCB2/nesfatin-1 mRNA or protein expression changes. 
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3.3 Materials and Methods 
3.3.1 Animal sample collection 
Animals used were described in the previous chapter. Briefly, they are a total of 24 WT 
and NKO mice treated with 50 μL PBS or E. coli O55:B5 LPS (L2880, Sigma-Aldrich, MO, 
USA) for 9 hours. All treatment groups have n=6 with the exception of NKO LPS where n=4. 
Samples in the experiments of this chapter include the paraffinized sections of left mouse lungs, 
BALF, and right mouse lungs collected as previously described, as well as peripheral blood. 
Peripheral blood was collected during the exsanguination of animals through cardiac puncture 
with a needle coated in heparin. Samples were kept at room temperature and sent to Prairie 
Diagnostic Services on the same day for complete blood cell count and differential blood count. 
From our lab’s previous experience of inducing ALI through LPS inhalation, 9 hours treatment 
time was chosen as the experimental end point where inflammatory response peaks. While 
experimental mice were bred on a C57BL/6 background, a previous study has found this strain to 
be hyporesponsive towards inhaled LPS which resulted in low immune cell counts in BALF 
(Lorenz et al., 2001). This is worth noting during result interpretation, but variation may also be 
present due to other factors such as mouse sub-strain, type of LPS used, and time of stimulation. 
WT and NKO mouse neutrophils were extracted from the bone marrow of subjects 
treated with PBS for 9 hours. To make up one biological replicate, bones from 2 WT or KO mice 
were pooled; 3 biological replicates were used in downstream experiments. During sample 
collection, mice pelvis, femur, and tibia were collected and stored in extraction buffer (PBS with 
2% FBS and 1 mM EDTA) on ice for same-day processing. Bones were crushed with a mortar 
and pestle in 3 washes of 1mL extraction buffer to release bone marrow cells. Neutrophils were 
then extracted using the EasySep™ Mouse Neutrophil Enrichment Kit (19762, STEMCELL 
Technologies, BC, Canada) following the exact protocols for purifying from the starting material 
of 2x10
8
cells. Two cytospins of ~5x10
5
 isolated cells are used to assess purity of processed 
samples; 100-150cells were counted for each and determined to have ≥90% neutrophil content 
before proceeding. Isolated cells were resuspended in IMDM media (ATCC) with 10% FBS 
(Life Technologies, CA, USA) at a concentration of 5x10
6
cells/mL.  
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3.3.2 Mouse neutrophil stimulation 
Mouse neutrophils suspended at 5x10
6
 cells in 1mL were plated into 12-well plates. Cells 
were then stimulated with 1 ng/mL E. coli O55:B5 LPS (L2880, Sigma-Aldrich, MO, USA) for 
0, 60, 90 and 120 mins respectively, and incubated at 37°C with 5% CO2. After stimulation, cells 
were resuspended through gentle pipetting, collected and separated from the culture media 
through centrifugation (100 RCF). Protease inhibitor cocktail was added to culture media 
samples, which were then stored at -80°C. Cells were lysed in 100 µL T-PER Tissue Protein 
Extraction Reagent (78510; Thermo Fisher Scientific, MA, USA) with protease inhibitor cocktail 
and stored in -80°C. 
3.3.3 Haematoxylin and eosin staining 
 To evaluate histological evidence of tissue injury, paraffinized sections of left mouse 
lungs as described in the previous chapter were stained with haematoxylin and eosin. Samples 
were first deparaffinized with xylene followed by decreasing concentrations of ethanol and 
dH2O. Samples were then placed in haematoxylin for 5 mins. The stain is washed off with tap 
water, dipped into 0.3% HCl in 70% ethanol 2 times, dipped into warm tap water 3 times and left 
in dH2O until all samples were processed. Samples were then placed into eosin for 6 mins. 
Excess solution was rinsed off with dH2O, and samples were quickly dehydrated with increasing 
concentrations of ethanol and xylene. Finally, samples were mounted and visualized under a 
light microscope. 
 Two researchers independently evaluated the slides, non-blinded, and qualitatively scored 
inflammation in perivascular, peribronchial and septal spaces. Scores are expressed as (+) no 
inflammation, (+ +) mild inflammation, (+ + +) moderate inflammation, and (+ + + +) heavy 
inflammation.  
3.3.4 Immunohistochemistry 
Next, we specifically examined neutrophil accumulation in LPS and PBS-treated mouse 
lungs by staining a neutrophil marker, Gr-1. Similar to previously described procedures, 
paraffinized sections were deparaffinized with xylene, and rehydrated with decreasing 
concentrations of ethanol, and dH2O. Samples were then placed in 0.5% H2O2 for 20 mins. After 
washing in PBS, pepsin (2 mg/mL in 0.01N HCl) was added to samples and incubated for 45 
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mins. Samples were then washed in PBS, blocked with 5% BSA for 30 mins, and incubated 
overnight in rat anti-mouse Gr-1 antibody (1:100; 550291; BD Biosciences, ON, Canada). The 
next day, samples were washed, and incubated in HRP-conjugated anti-rat secondary antibody 
(1:200; P0450; Dako, CA, USA) for 30 mins. Samples were washed in PBS, and color was 
developed using VECTOR VIP Peroxidase Substrate Kit (VECTOR Laboratories, ON, Canada) 
for 5 mins. Slides were washed in dH2O and counter-stained in methyl green for 1 min, washed 
in dH2O and dehydrated using increasing concentrations of ethanol followed by xylene. Lastly, 
samples were mounted and visualized under a light microscope. Isotype and negative controls 
were included with this set of samples. 
In order to separately evaluate neutrophil accumulation in alveolar spaces and interstitial 
spaces, 5 pictures of each region were taken at high power magnification to establish neutrophil 
counts. Since Intratracheal administration of LPS is known to result in patchy injury where areas 
of the lung may be spared, randomly selected areas were only chosen if they were also 
representative of injury (Matute-Bello et al., 2010). 
3.3.5 BALF processing  
To examine the alteration of alveolar capillary barrier as a result of inflammation, 
changes in protein concentration in BALF is measured. In addition, inflammatory response can 
also be measured through an absolute count of immune cells, an absolute count of neutrophils, 
and the differences of cytokine concentrations in BALF. 
After collecting BALF through the trachea with 3 aspirations of 0.5 mL PBS, samples 
were immediately stored on ice. Cell counts were performed on the same day where cells from 
the BALF were spun down at 100RCF for 5 mins, resuspended in 1 mL, and counted using a 
haemocytometer. Following absolute counts of immune cells, samples were once again spun 
down and resuspended in 200 µL PBS to produce 2 cytospin slides (100 RCF, 3 mins). The 
slides were then stained using the Hemacolor® Stain Set (65044-93; Millipore Sigma, ON, 
Canada) and visualized under a light microscope where pictures were taken for differential cell 
counting; around 100 cells were counted per sample and absolute neutrophil counts were 
estimated using absolute immune cell counts. BALF supernatant were stored in -80°C for ELISA 
that would be performed later. 
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3.3.6 Protein assay   
 In order to determine the differences in protein concentration of BALF samples, a DC™ 
protein assay (5000112; Bio-Rad, CA, USA) was performed exactly as instructed by Bio-Rad 
protocols. Samples were incubated for 15 mins and analyzed with a plate reader. Sample values 
were averaged between replicates, and a standard curve of BSA was included to quantify sample 
signals. Total protein concentration was calculated by multiplying protein concentration by 
BALF volume and dividing by total volume of PBS used (1.5 mL). 
3.3.7 ELISA 
 To determine the difference in cytokine concentration of BALF from WT and NKO LPS 
and PBS-treated lungs, 50 μL of undiluted sample from each mouse was analyzed with a Bio-
Plex Pro™ Mouse Cytokine 23-plex assay (#M60009RDPD; Bio-Rad, CA, USA) following the 
supplier’s protocol. Samples were loaded in duplicates, and signal detection was done using the 
Luminex Bio-Plex 200 system. The exact same procedure was then repeated on cell culture 
media samples of mouse neutrophils to elucidate cytokine concentration differences between WT 
and NKO samples treated 0, 60, 90 and 120 mins with 1 ng/mL LPS. ELISA results from BALF 
were normalized through multiplying the cytokine concentration by the volume of BALF, then 
dividing the total cytokine concentration by total PBS used for BALF extraction (1.5 mL). 
3.3.8 Myeloperoxidase Assay 
As an indirect method of quantifying neutrophils remaining in the lungs after BALF 
extraction, a myeloperoxidase (MPO) assay is performed. A section of the right mouse lung 
(stored at -80°C) was first homogenized in 500 μL 50 mM HEPES (pH 8.0) using the Retsch 
MM400 oscillating mill (frequency: 30/s; 30 secs). Samples were then centrifuged at 10,000 g 
for 20 mins. Supernatant was discarded, the pellet was resuspended in 500 μL 0.5% CTAC and 
homogenized again. After centrifuging the sample once more, supernatant was aliquot into new 
tubes. A standard curve was made up using myeloperoxidase from human leukocytes (M6908-
5UN; Sigma-Aldrich). In each well, 10 μL of homogenized sample was combined with 65 μL 
phosphate citrate; samples were analyzed in duplicates. Afterwards, 100 μL of TMB substrate 
was added and color was allowed to develop for 5 mins. 150 μL stop solution was added upon 
completion, and signals were measured at O.D. 450 nm with a plate reader. 
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In order to standardize readings to the amount of protein present, an accompanying 
protein assay was also performed as described in section 3.3.6. 
3.3.9 Reverse transcription quantitative PCR (RT-qPCR) 
 To assess NUCB2/nesfatin-1 mRNA expression in mouse lungs, a section of the right 
mouse lung (previously stored in -80°C) was homogenized in 1 mL TRIzol™ (15596026; 
Thermo Fisher Scientific, MA, USA) using the VC300 VibraCell sonicator (30 secs ON, 1 min 
OFF; 2 cycles). RNA was then extracted using the exact protocol provided by Invitrogen. RNA 
pellets were dissolved in 30 μL RNase-free water and quantified with a Nanodrop. Reverse 
transcription was then performed with the QuantiTect Reverse Transcription Kit (205311; 
QIAGEN) following the exact protocol provided for 1 μg starting material. Quantitative real-
time PCR was performed using Bio-Rad CFX96 Touch™ instrument and SsoAdvanced 
Universal SYBR Green Supermix (1725272; Bio-Rad, CA, USA). NUCB2 (FP: 3' 
CCAGTGGAAAATGCAAGGAT 5’ and RP: 3’ GCTCATCCAGTCTCGTCCTC 5’) and 
GAPDH (FP: 3’ CTCAACGACCACTTTGTCAAGCTCA 5’ and RP: 3’ 
GGTCTTACTCCTTGGAGGCCATGTG 5’) primers were obtained from Invitrogen (CA, 
USA). Melting curves, no template and no reverse transcription controls were analyzed after 
each run to ensure specificity. GAPDH was used as a reference gene for sample normalization.    
 3.3.10 Western blot 
 NUCB2/nesfatin-1 protein expression in WT mouse lungs, and neutrophils stimulated 
with LPS for 0, 60, 90 and 120 mins, were examined through Western blots. Mouse lungs were 
homogenized in T-PER Tissue Protein Extraction Reagent (Thermo Fisher Scientific, MA, USA) 
with protease inhibitor cocktail at frequency of 30/s for 30 secs using the Retsch MM400 
oscillating mill, and mouse neutrophils (5x10
6
 cells per sample) were lysed in 100 μL RIPA 
buffer with protease inhibitor cocktail. 
Samples were heated in Laemmli buffer at 95°C for 5 mins, run on 12% SDS-PAGE gels 
and transferred onto nitrocellulose membranes. Membranes were blocked for 1 hour using 5% 
skim milk in TBS-T. All antibodies were diluted in 5% skim milk in TBS-T. A custom rabbit 
anti-NUCB2 antibody (1:1000; 1mg/mL; Pacific Immunology, CA, USA) raised against a 
synthetic peptide, VDKTKVHNTEPVENARIEP-Cys (20 AA), was used as the primary 
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antibody and incubated overnight. Following, anti-rabbit Alexa Fluor® 488 (1:5000; A-11008; 
Thermo Fisher Scientific, MA, USA) was used as the secondary antibody and incubated for 30 
mins at RT. Signal detection was done on the GE Healthcare Typhoon 9400 imager. The blot 
was then stripped and reprobed using rabbit anti-β-actin antibody (1:2000; ab8227; Abcam, ON, 
Canada), incubated overnight, incubated in anti-rabbit Alexa Fluor® 488 (1:5000; A-11008; 
Thermo Fisher Scientific, MA, USA) for 30mins at RT and imaged. All densitometry was 
performed using Image J.  
3.3.11 Data Analysis 
 2-sample t-tests and repeated measures one-way ANOVA were used for sample 
comparisons; p-values ≤0.05 were considered statistically significant. Results are presented as 
Mean ± SEM with 6 biological replicates per group, except in the NKO LPS group where n=4. 
GraphPad Prism 7 (Avenida de la Playa, CA, USA) was used for all analysis.  
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3.4 Results 
3.4.1 NKO mouse lungs show slightly more immune cell accumulation compared to WT in LPS 
treated samples  
 To assess histological evidence of tissue injury, mouse lungs were stained with 
haematoxylin and eosin where 3 regions- perivascular, peribronchiolar and septal spaces- were 
then scored for signs of inflammation such as immune cell accumulation, presence of hyaline 
membrane, proteinaceous debris in alveolar spaces and alveolar septal thickening (Matute-Bello 
et al., 2010). As structural damage is not expected in ALI models, the following assessment 
mostly account for immune cell accumulation (Matute-Bello et al., 2010). Table 3.1 summarizes 
our findings in the 4 groups of animals. We observed that none of the WT and NKO PBS-treated 
samples showed any signs of inflammation. In contrast, WT LPS-treated samples showed 
moderate inflammation, and NKO LPS-treated samples showed moderate to heavy levels of 
inflammation in all regions assessed. To illustrate these differences, Figure 3.1 shows 
representative images for each group. Figure 3.1C and D, in particular, demonstrate the higher 
immune cell accumulation observed in perivascular and septal spaces of NKO LPS-treated lungs 
compared to WT.  
 No other signs of tissue injury including presence of hyaline membranes, fibrin strands or 
thickened alveolar walls were observed. Similar to WT mice, we confirm that LPS-treatment in 
NKO mice did not result in pulmonary structural damage. As can be seen in Figure 3.1, the 
alveolar septa of all samples remain intact. There are no signs of cells sloughing in bronchioles, 
or presence of hyaline membranes. 
3.4.2 Loss of NUCB2/nesfatin-1 increases neutrophil accumulation in LPS-treated mouse lungs 
 Next, we looked more specifically into neutrophil accumulation in PBS or LPS-treated 
lungs through immunohistochemistry using a neutrophil marker, Gr-1. Regions representative of 
injury were randomly selected in each sample, and neutrophils were counted at high power 
magnification (40X) for 2 regions of interest: alveolar spaces (n=5) and interstitial spaces (n=5).  
 In alveolar spaces of LPS-treated samples, mean neutrophil counts were 3 times higher in 
NKO than WT lungs (p=0.038; Figure 3.2A). Counts were not significantly different in 
interstitial spaces (p=0.072; Figure 3.2B). Figure 3.2C shows representative images of LPS-
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treated samples, illustrating the difference in neutrophil accumulation between NKO and WT 
lungs. Since non-adherent neutrophils were collected during the BALF extraction process, this 
population is representative of adherent neutrophils. 
In PBS-treated samples, neutrophils were scarce throughout WT and NKO lungs and 
counts were not significantly different (Figure 3.2D). During this assessment, we were able to 
confirm the presence of marginated neutrophils in both groups, indicating that the process is not 
affected by the absence of NUCB2. 
Negative and isotype controls performed support the validity of the IHC protocol (Figure 
3.2E). 
3.4.3 Vascular permeability is not significantly different between WT and NKO PBS or LPS-
treated samples  
 To determine whether knocking out NUCB2 results in alteration of alveolar capillary 
barrier, a protein assay was performed on BALF extracted from PBS or LPS-treated WT and 
NKO mouse lungs.  
 Total protein concentration between WT and NKO LPS or PBS-treated samples were not 
significantly different (Figure 3.3). However, LPS treatment does increase vascular permeability 
in both genotypes compared to PBS treatment. WT LPS samples had 1.7 times the mean total 
protein concentration of PBS-treated samples (p=0.044), while NKO LPS samples had 2.4 times 
the mean total protein concentration of NKO PBS samples (p<0.001). 
3.4.4 Absolute immune cell and neutrophil counts in BALF of NKO and WT mice do not 
significantly differ 
 To measure inflammatory response of NKO and WT mouse lungs, we first examined 
absolute immune cell counts in BALF, and then looked more specifically at absolute neutrophil 
counts. Since these neutrophils were flushed out during the process of BALF collection, they 
represent the population of non-adherent neutrophils within each sample. Around 100 cells 
examined during differential cell counts and absolute neutrophil counts were estimated based on 
absolute immune cell counts. 
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 Although the number of total immune cells and neutrophils in BALF increased with LPS 
treatment compared to PBS treatment, WT and NKO samples were not significantly different 
following PBS or LPS-treatment (p=0.778 and p=0.334 respectively; Figure 3.4). In LPS-treated 
groups, we note that the mean absolute immune cell count and mean absolute neutrophil count 
were both 1.7 times and higher in NKO samples compared to WT (p=0.334 and p=0.326 
respectively). 
3.4.5 Myeloperoxidase activity is not significantly different between NKO and WT LPS-treated 
lungs   
Next, we used an indirect method to quantify adherent neutrophils where 
myeloperoxidase (MPO), an anti-microbial protein abundant in activated neutrophils, is assayed 
using lung homogenates. A corresponding protein assay was performed to normalize readings, 
and MPO activity is expressed in terms of U/mg protein.   
MPO activity between NKO and WT PBS or LPS-treated lungs were not statistically 
different (Figure 3.5). In LPS-treated samples, we observed that the mean MPO activity in NKO 
mouse lungs was 1.4 times higher than WT (p=0.074). MPO activity in LPS-treated NKO mouse 
lungs was also 2.6 times higher than those treated with PBS (p<0.0001). In comparison, LPS-
treated WT lungs had 1.9 times higher MPO activity compared to those given PBS (p=0.010). 
3.4.6 Loss of NUCB2/nesfatin-1 increases concentration of cytokines associated with 
inflammatory response in BALF 
 To determine whether knocking out NUCB2 changes the concentration of cytokines 
involved in inflammatory responses, an ELISA was performed on BALF samples for a panel of 
23 different cytokines.   
 Amongst the 23 cytokines, 5 were found to be statistically different between LPS-treated 
WT and NKO samples (Figure 3.6A; Table 3.2). Starting from the largest effect size, IL-5 in 
NKO samples was 2.3 times higher in mean total concentration than WT (p=0.014); TNFα, 2.2 
times (p=0.028); MIP-1β, 2.1 times (p=0.001); MIP-1α, 2.0 times (p=0.029); G-CSF, 1.6 times 
(p=0.029). 
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 Close to the significance value of p≤0.05, IL-6 was expressed in NKO samples at 1.8 
times higher mean total concentration than WT (p=0.052; Figure 3.6B). 
 IL-17 (p=0.079), KC (p=0.100), GM-CSF (p=0.109), IFN-γ (p=0.134), IL-13 (p=0.143), 
IL-12(p70) (p=0.161), RANTES (p=0.307), IL-1α (p=0.328), IL-12(p40) (p=0.344), IL-1β 
(p=0.461), MCP-1 (p=0.482), IL-10 (p=0.517) and eotaxin (p=0.649) were not statistically 
different (Figure 3.6B). Signals were not detected for the following assayed cytokines: IL-2, IL-
3, IL-4 and IL-9 (data not shown). 
3.4.7 Loss of NUCB2/nesfatin-1 does not affect peripheral blood cell counts in PBS or LPS treated 
mice 
 Next, we assessed whether NUCB2/nesfatin-1 had any systemic influence on peripheral 
blood counts following PBS or LPS treatment. Specific parameters tested include absolute 
immune cell, lymphocyte and neutrophil counts, neutrophil-total white blood cell (WBC) ratio 
and neutrophil-lymphocyte ratio (NLR). 
Results of peripheral blood analysis are shown in Figure 3.7. When LPS-treated WT and 
NKO mice were compared, there were no significant differences in absolute immune cell 
(p=0.133), lymphocyte (p=0.470) and neutrophil (p=0.073) counts, or NLR (p=0.331). Similarly, 
PBS-treated WT and NKO mice showed no significant differences in absolute immune cell 
(p=0.421), lymphocyte (p=0.582) and neutrophil (p=0.193) counts, or NLR (p=0.475).  
Close to the significance value, the ratio of neutrophils to total WBC show that the mean 
ratio in NKO samples is 0.9 times that of WT in LPS-treated samples (p=0.057).  
3.4.8 NUCB2/nesfatin-1 mRNA and protein expression in mouse lungs do not change with LPS 
stimulation 
 To determine whether mRNA or protein expression of NUCB2/nesfatin-1 changes with 
inflammation of mouse lungs, we performed RT-qPCR and Western blots respectively on 
mRNA and protein isolated from portions of frozen lung tissue.  
Using GAPDH as the reference gene in RT-qPCR, samples were normalized and the 
∆∆Cq calculation method was used to compare between PBS and LPS-treated WT samples. 
Results revealed no significant difference in mRNA expression between the two groups (Figure 
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3.8A). Similarly, Western blot analysis using β-actin to normalize between samples revealed no 
significant difference in protein expression between the two groups (Figure 3.8B, C). 
3.4.9 Inflammatory cytokine concentrations following LPS stimulation were not significantly 
different between WT and NKO mouse neutrophils  
 Following the comparison of inflammatory cytokine concentrations in BAL fluid of WT 
and NKO mouse lungs with LPS treatment, we wanted to more specifically examine the role of 
neutrophils in our observations. To this end, bone marrow neutrophils were extracted from PBS-
treated mice and stimulated with LPS for 0, 60, 90 and 120 mins. Each biological replicate was 
composed of pooled neutrophils from 2 mice (n=3). Cell culture media, containing all secreted 
cytokines, were then analyzed with a 23-plex ELISA. Results indicated that only 7 cytokines 
were present at detectable levels: IL-1α, IL-6, TNF-α, RANTES, MIP-1α, MIP-1β, and IL-
12(p70).  
 Repeated measures two-way ANOVA revealed an interaction between LPS stimulation 
time and genotype on the concentration of IL-6 in culture supernatant (p=0.036). Subsequent 
Sidak’s multiple comparisons test revealed that knocking out NUCB2 led to a significant 
decrease of IL-6 at LPS120 (p=0.017; Figure 3.9).  
With all other cytokines, time (p<0.005) but not genotype (p>0.164) was the significant 
source of variation. In both WT and NKO samples, expression of these cytokines increased with 
LPS stimulation time, but no significant differences were identified comparing WT and NKO 
samples at each time point. 
3.4.10 NUCB2/nesfatin-1 protein expression in mouse neutrophils does not change with LPS 
stimulation 
 Lastly, Western blots were used to determine whether NUCB2/nesfatin-1 expression in 
mouse neutrophils change with 0, 60, 90 and 120mins of LPS stimulation (n=3). β-actin was 
used as the reference gene for normalization. Densitometry was performed and data was 
analyzed using repeated measaures one-way ANOVA. 
Results revealed no significant difference in NUCB2/nesfatin-1 expression between time 
points (p=0.436; Figure 3.10).  
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  Perivascular Peribronchiolar Septal 
WT PBS + + + 
NKO PBS + + + 
WT LPS + + + + + + + + + 
NKO LPS + + +/+ + + + + + + + + +/+ + + + 
Table 3.1: Scoring of perivascular, peribronchiolar and septal spaces for inflammation.  
(+: no inflammation, + + mild inflammation, + + + moderate inflammation, + + + + heavy inflammation) 
 
  NKO/WT Total Protein Concentration (LPS-treated) p-value 
IL-5 2.3 0.014 
TNFα 2.2 0.028 
MIP-1β 2.1 0.001 
MIP-1α 2.0 0.029 
G-CSF 1.6 0.029 
IL-6 1.8 0.052 
IL-17 1.2 0.079 
KC 1.6 0.100 
GM-CSF 1.8 0.109 
IFN-γ 1.1 0.134 
IL-13 1.3 0.143 
IL-12(p70) 1.4 0.161 
RANTES 1.3 0.307 
IL-1α 1.3 0.328 
IL-12(p40) 1.3 0.344 
IL-1β 1.1 0.461 
MCP-1 1.3 0.482 
IL-10 1.1 0.517 
Eotaxin 0.8 0.649 
Table 3.2: ELISA of BALF from LPS-treated mouse lungs.  
To emphasize effect size, this table compares cytokine concentrations by dividing concentrations in NKO 
samples by that in WT (n=4-6). P-values represent the degree of statistical significance when the 2 groups 
are compared through a student’s t-test. Statistically significant results are arranged in order of effect size; 
statistically insignificant results (p≥0.05; below red line) are arranged by p-values. 
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Figure 3.1: Haematoxylin and eosin staining.  
Representative images of (A) WT PBS, (B) NKO PBS, (C) WT LPS, and (D) NKO LPS mouse lung 
sections stained with haematoxylin and eosin (n=4-6). B: Bronchiole; V: vein. Scale bar = 100 μm 
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Figure 3.2: Neutrophil counts at high power magnification (40X) through immunohistochemistry of 
Gr-1.  
Neutrophils identified through immunohistochemical staining of Gr-1 were counted at high power 
magnification (40X) for (A) alveolar spaces, and (B) interstitial spaces; counts were averaged between 5 
fields per sample. Representative images for (C) LPS-treated samples show neutrophil accumulation in 
interstitial and alveolar spaces, and (D) PBS-treated samples show neutrophil margination around small 
capillaries and resident neutrophils in alveolar spaces. (E) Controls included secondary antibody only 
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(negative control) and staining with Rat IgG2b (isotype control). Raw data were analyzed through 2-
sample t-tests (*p≤0.05; n=4-6; results presented as Mean ± SEM).  
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Figure 3.3: Total protein concentration in BALF.  
Total protein concentration of BALF was determined through a DC protein assay. There were no 
significant differences between WT and NKO LPS or PBS-treated samples. (*p≤0.05 compared to WT 
PBS; ***p≤0.001 compared to NKO PBS; n=4-6; results presented as Mean ± SEM). 
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Figure 3.4: Absolute cell counts in BALF.  
(A) Absolute immune cell counts were performed on BALF extracted. (B) Following, differential cell 
counts were performed on around 100 cells per sample and absolute neutrophil counts were estimated 
based on absolute immune cell counts. Results revealed no significant difference between WT and NKO 
samples; statistical significance only found when comparing PBS and LPS treatments of the same 
genotype (*p≤0.05, **p≤0.01 compared to PBS treatment of the same genotype; n=4-6; results presented 
as Mean ± SEM). 
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Figure 3.5: Assay of myeloperoxidase activity in mouse lung homogenates.  
A uniform volume of mouse lung homogenate was assayed for each sample to determine its 
myeloperoxidase activity, and then normalized against sample protein concentration to produce final data. 
Differences between LPS-treated WT and NKO samples were close to achieving statistical significance 
(p=0.074). PBS and LPS treatments were statistically different within the same genotype. (*p≤0.05, 
**p≤0.0001 compared to PBS treatment of the same genotype; n=4-6; results presented as Mean ± SEM). 
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Figure 3.6: 23-plex ELISA of BALF.  
An ELISA performed on the BALF of LPS or PBS-treated mouse lungs reveal (A) statistically significant 
differences between NKO and WT groups treated with LPS in concentrations of IL-5, TNF-α, MIP-1β, 
MIP-1α and G-CSF ordered according to effect size. (B) Results for IL-6, IL-17, KC, GM-CSF, IFN-γ, 
IL-13, IL-12(p70), RANTES, IL-1α, IL-12(p40), IL-1β, MCP-1, IL-10 and eotaxin were not statistically 
significant. Signals for IL-2, IL-3, IL-4 and IL-9 were not within detectable range (data not shown). 
(*p≤0.05, ***p≤0.001. Letters represent statistically significant differences compared with its PBS 
counterpart, a: p≤0.05, b: p≤0.01, c: p≤0.001, d: p≤0.0001. Groups with ≥4 samples below detection limit 
are categorized as not detected (n.d.); n=4-6. Results are presented as mean ± SEM.) 
  
83 
  
 
Figure 3.7: Peripheral blood analysis.  
Peripheral blood from WT and NKO mice treated with LPS or PBS were analyzed in terms of absolute 
immune cell, lymphocyte and neutrophil count, neutrophil-lymphocyte ratio, and neutrophil-WBC ratio. 
Results were not statistically significant (p≤0.05). (Results are presented as mean ± SEM)  
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Figure 3.8: RT-qPCR quantification and Western blot of NUCB2/nesfatin-1 in WT PBS and LPS-
treated mouse lungs.  
Quantification of NUCB2/nesfatin-1 (A)mRNA expression through RT-qPCR and (B)protein expression 
through Western blots in WT PBS and LPS-treated mouse lungs revealed no significant difference 
between the two groups (n=6). NKO sample shows the presence of antibody non-specificity. (C) 
Graphical representation of Western blot densitometry analysis (n=6). (Results presented as Mean ± 
SEM.) 
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Figure 3.9: 23-plex ELISA of mouse neutrophil culture supernatant.  
An ELISA performed on the culture supernatant of mouse neutrophils stimulated with 1ng/mL LPS for 0, 
60, 90 and 12mins reveal no significant differences between WT (grey) and NKO (black) for IL-1α, TNF-
α, RANTES, MIP-1α, MIP-1β, and IL-12(p70) cytokine expression (p>0.121). Sidak’s multiple 
comparisons following a repeated measures two-way ANOVA indicated that IL-6 was significantly lower 
at LPS120 in NKO samples (p=0.017). All LPS stimulated samples were standardized against their 
* 
* 
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respective control samples. Signals for other assayed cytokines were not within detectable range (data not 
shown). (Results are presented as Mean ± SEM.)  
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Figure 3.10: Western blot of NUCB2/nesfatin-1 in WT neutrophils.  
Quantification of NUCB2/nesfatin-1 in WT mouse neutrophils treated with 1ng/mL LPS for 0(Ctrl), 60, 
90 and 120mins. (A) Representative image of Western blot results for one set of samples. (B) Graphical 
representation of Western blot densitometry analysis (n=3). Results analyzed using repeated measures 
one-way ANOVA revealed no significant difference in NUCB2/nesfatin-1 protein expression (p=0.436). 
(Results presented as Mean ± SEM.) 
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3.5 Discussion  
 Acute lung injury(ALI) is a pulmonary inflammatory condition with multiple causes that 
can broadly be divided into local injuries such as pneumonia, ventilatory damage and blunt chest 
trauma, and systemic risk factors such as sepsis, large volume blood transfusions and burn 
injuries (Flierl et al., 2006). While no animal model is capable of replicating all symptoms of 
human ALI, parameters determined upon consensus of researchers surveyed by the American 
Thoracic Society have been established to assess ALI in mouse models (Matute-Bello et al., 
2010). These characteristics of ALI include histological evidence of tissue injury, change in 
alveolar-capillary membrane integrity, inflammatory response, and physiological evidence of 
dysfunction (Matute-Bello et al., 2010). In our ALI mouse model, we addressed the first 3 of 
these characteristics using adult (3-5 months old) male C57BL/6-
Tyrc-Brd 
WT and NUCB2 
KO(NKO) mice intranasally stimulated with E. coli O55:B5 LPS for 9 hours to induce ALI 
caused by neutrophil infiltration and sepsis. The above parameters are important since any 
variation would alter the degree or nature of responses. Our experiments mainly focus on 
differences between WT and NKO mouse lungs and neutrophils to elucidate the potential role of 
NUCB2/nesfatin-1 in lung inflammation. Nonetheless, the role of the above parameters on our 
results will be briefly discussed to highlight possible refinements to our experiments. While 
previous studies of NUCB2/nesfatin-1 in inflammation all involve the addition of nesfatin-1 into 
their experimental model, our studies are unique in the use of NKO mice, and insight through 
inducing inflammation in the absence of our protein of interest. 
 In assessing the characteristics of ALI, our results showed a significant increase in 
neutrophil and inflammatory cytokine accumulation in NKO mouse lungs compared to WT. 
While previous studies have shown significantly reduced levels myeloperoxidase (MPO) 
activity- an indirect measure of neutrophil infiltration- in brain tissues of nesfatin-1 treated rats 
compared to untreated samples (Ozsavci et al., 2011), our immunohistological results of Gr-1 
stained neutrophils are the first to present illustrative evidence of enhanced neutrophil 
accumulation in the absence of NUCB2/nesfatin-1. Our results showed mean neutrophil counts 
at high power magnification to be 3 times higher in NKO samples compared to WT. Since we 
know that ALI induced through intranasal injection of LPS would result in patchy injury, our 
method of assessing neutrophil infiltration through counts enables us to randomly select areas 
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representative of injury. This advantage to experimental relevance comes at the cost of possible 
experimenter bias. Hence to support our findings, an assay to compare MPO activity between 
WT and NKO mouse lung homogenates was also performed. A small section of each mouse lung 
was randomly sampled without knowledge of its state of injury. Although the results were not 
statistically significant, the 1.4 times higher MPO activity in NKO samples compared to WT 
(p=0.074) was supportive of our findings. Further, taking into consideration our small sample 
size of 6 animals per group, we propose that statistical significance for this particular experiment 
would only be a matter of increasing animal numbers. Another interpretation of present results is 
that myeloperoxidase may be less active in the absence of NUCB2/nesfatin-1, which in turn 
affected the ability of an MPO assay to indirectly quantify neutrophils. Increased neutrophil 
infiltration in the absence of NUCB2/nesfatin-1 not only implicates the potential for increased 
oxidative damage and pro-inflammatory cytokine release, but also additional stress on 
macrophages during clearance to resolve inflammation. This will be further discussed later as we 
specifically examine WT and NKO mouse neutrophils. 
 In terms of changes in alveolar-capillary permeability, there results showed no 
statistically significant differences in total protein concentration of BALF between WT and NKO 
LPS or PBS-treated samples. Both WT and NKO total protein concentrations were higher in 
LPS-treated samples compared to PBS samples, signaling that vascular permeability was 
increased as a result of inflammatory stimulation.  
 In our final measure of ALI, absolute immune cell and neutrophil counts, and cytokine 
expression in BALF of NKO and WT mice were used to assess inflammatory response. The 
expression of 5 cytokines were significantly elevated in NKO samples compared to WT, but no 
significant difference was found between WT and NKO absolute immune cell and neutrophil 
counts. While the loss of NUCB2/nesfatin-1 increases the adherent population of neutrophils in 
mouse lungs, these results suggest the non-adherent neutrophil population remains unaffected. 
Previous studies have found C57BL/6 mice to be LPS-hyporesponsive, displaying consistently 
low concentrations of polymorphonuclear leukocytes, TNF-α, and MIP-2 in BALF compared to 
other mouse strains such as 129/Svlm and C3H/BfeJ (Lorenz et al., 2001). As such, our 
experimental model may simply not be sensitive enough to detect any significant difference 
between treatment groups.  
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 Amongst the many inflammatory cytokines, previous research on human lung 
inflammation induced by intratracheal instillation of LPS showed increased levels of TNF-α, IL-
1β, IL-6, G-CSF, IL-8, MCP-1, MIP-1α and MIP-1β (O’Grady et al., 2001). From our results, 
TNF-α, G-CSF, MIP-1α and MIP-1β were expressed at significantly higher levels in LPS-treated 
NKO BALF samples compared to WT. These observations provide important hints as to which 
cytokines relevant to LPS-induced human lung inflammation are affected by NUCB2/nesfatin-1. 
At length, our results showed that IL-5, TNF-α, MIP-1α, MIP-1β and G-CSF expression were 
significantly higher in NKO than WT; IL-6 also had higher expression in NKO samples than 
WT, but was slightly short of statistical significance (p=0.052); results for IL-17, KC, GM-CSF, 
IFN-γ, IL-13, IL-12(p70), RANTES, IL-1α, IL-12(p40), IL-1β, MCP-1, IL-10 and eotaxin were 
not statistically significant; IL-2, IL-3, IL-4 and IL-9 expression was below detectable levels. 
Cytokines expressed at significantly higher levels in NKO samples could be divided into pro-
inflammatory cytokines (TNF-α and G-CSF) and chemokines (MIP-1α and MIP-1β) that 
participate in the acute phase reaction, and a mediator of allergic inflammation (IL-5) (Xu et al., 
1996; Tumpey et al., 2002; Lee et al., 2014). These results agree with previous findings in 
animal studies where NUCB2/nesfatin-1 was shown to play an anti-inflammatory role (Ozsavci 
et al., 2011; Tang et al., 2012). While LPS treatment itself is not expected to produce allergic 
inflammation in mice, the elevated levels of IL-5 with LPS treatment could be an indication of 
previous exposure to allergens (Lee et al., 2014). Differential cell counts performed on BALF 
showing elevated lymphocyte counts in 4 out of 12 PBS-treated samples, but none of the LPS-
treated samples, implicate this as a possibility. These results suggest that the increased neutrophil 
accumulation observed in NKO mice contributes to increased pro-inflammatory cytokine 
expression. While not explored in this experiment, we propose that NUCB2/nesfatin-1 may also 
increase macrophage pro-inflammatory cytokine expression since TNF-α, MIP-1α, MIP-1β and 
G-CSF are all cytokines secreted by macrophages to initiate acute inflammation (O’Grady et al., 
1999; Xu et al., 2000; Duque and Descoteaux, 2014). 
 In addition to the parameters above that help us assess the extent of ALI in WT and NKO 
mouse lungs, we observed that the absence of NUCB2/nesfatin-1 in mouse lungs did not 
compromise its macroscopic structural integrity during PBS or LPS treatment. Neutrophil 
margination appeared, likewise, unaffected in PBS-treated lungs. A brief analysis of peripheral 
blood counts revealed no significant difference between WT and NKO animals treated with LPS 
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or PBS. However, we do note the 0.9 times neutrophil to total white blood cell ratio in LPS-
treated NKO samples compared to WT that was close to statistical significance (p=0.057). This 
provides additional support to the observed increased neutrophil recruitment to the lungs as they 
are depleted from peripheral circulation. 
 To take a more specific look into the role of NUCB2/nesfatin-1 in mouse neutrophils 
during ALI, we performed an identical 23-plex ELISA on the neutrophil culture supernatant after 
5x10
6
 cells were stimulated for 0, 60, 90 and 120 mins with 1 ng/mL LPS. The 1 ng/mL LPS 
concentration was selected based on previous studies in human neutrophils demonstrating 
different dosages that enhanced phagocytosis and oxidative burst compared to LPS-free controls 
(Bohmer et al., 1992). It was also determined to be a physiologically relevant dosage based on 
endotoxin levels present in serum of septic patients (Levin et al., 1970). Our results showed that 
the only cytokines present at detectable levels were IL-6, IL-1α, MIP-1α, MIP-1β, TNF-α, 
RANTES and IL-12(p70). After normalizing results against their respective controls, we found 
that only NKO neutrophils after 120 mins of LPS stimulation had significantly lower expression 
of IL-6 than WT. Previous studies have shown IL-6 to enhance neutrophil migration towards IL-
8, reduce neutrophil deformability, and stimulate neutrophil release from bone marrow in 
response to LPS treatment (Walker et al., 2008; Wright et al., 2014). However, it is worth noting 
that macrophages are also a major source of IL-6 (Duque and Descoteaux, 2014), hence 
decreased expression from neutrophils alone should be interpreted with caution. Although 
statistically insignificant, we observed that all detected cytokines except IL-1α were secreted at 
higher concentrations by WT neutrophils than NKO after LPS stimulation; cytokine 
concentrations in the supernatant generally increased with stimulation time. Since only 3 
biological replicates were performed; an increase in sample size is expected to increase 
sensitivity to the observed change in effect size. Our observations agree with previous findings 
where expression of inflammatory cytokines was upregulated with the presence of 
NUCB2/nesfatin-1 (Scotece et al., 2014). With our observation that NKO mouse lungs had 
approximately 3 times the adherent neutrophil population of WT, our findings integrate the 
seemingly contradictory results of NUCB2/nesfatin-1 being anti-inflammatory and pro-
inflammatory in animal and cell culture studies respectively (Ozsavci et al., 2011; Tang et al., 
2012; Scotece et al., 2014). We propose that while neutrophils individually secrete less 
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inflammatory cytokines the absence of NUCB2/nesfatin-1, increased accumulation results in an 
effect that is net pro-inflammatory.  
 Last, while studies have shown that NUCB2/nesfatin-1 mRNA and protein expression in 
adipocytes and chondrocytes increased with pro-inflammatory stimulus, our results revealed no 
change of mRNA and protein expression in mouse lung homogenates, and no change of protein 
expression in mouse neutrophil lysates following LPS treatment (Ramanjaneya et al., 2010; 
Scotece et al., 2014).  
 Taken together, our findings suggest NUCB2/nesfatin-1 to be an anti-inflammatory 
cytokine. The absence of NUC2/nesfatin-1 not only significantly increased adherent neutrophil 
accumulation, but also pro-inflammatory cytokines and chemokines. Vascular permeability was 
not significantly affected by the loss of NUCB2/nesfatin-1. Inflammatory stimulus with LPS in 
WT mice also did not change NUCB2/nesfatin-1 mRNA and protein expression in mouse lungs, 
or protein expression in mouse neutrophils. 
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CHAPTER 4. GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 The primary objectives of this project were to determine the localization, expression and 
function of NUCB2/nesfatin-1 in normal and inflamed human and mouse lungs. Experiments 
were carried out with a focus on the role of neutrophils during inflammatory conditions as they 
are important mediators in many pulmonary inflammatory conditions such as chronic obstructive 
pulmonary disease (COPD) and acute lung injury/acute respiratory distress syndrome 
(ALI/ARDS) which are typically associated with high mortality rates (Liu et al., 2017). While 
NUCB2/nesfatin-1 is known to be expressed in mouse lungs (Chung et al., 2013), implicated to 
have a role in inflammation (Ozsavci et al., 2011; Tang et al., 2012), and expressed in plasma at 
levels that positively correlate with pro-inflammatory cytokines (IL-6, IL-8, TNF-α and MMP-9) 
during human COPD (Leivo-Korpela et al., 2014), our study is the first to investigate its role in 
ALI. In contrast to previous studies, our experiments make use of WT and NUCB2 KO (NKO) 
mice as supposed to administering additional nesfatin-1 to our models. By performing studies on 
both animal models and cell culture, we also bridge the gap of knowledge as to whether 
NUCB2/nesfatin-1 has a pro- or anti- inflammatory effect. 
 In the first part of our studies, we determined the localization of NUCB/nesfatin-1 in 
normal and inflamed human and mouse lungs and neutrophils. Prior to our experiments, there 
were only published results of its mRNA and protein expression in mouse lungs; no studies had 
looked into human lungs or given any localization information (Chung et al., 2013; Kim et al., 
2014). In addition, a study by Stengel et al. (2011) suggested that NUCB2/nesfatin-1 mRNA was 
not detectable in rat white blood cells; this was later disputed as Ravussin (2016) demonstrated 
that NUCB2/nesfatin-1 mRNA was present in macrophages and T cells. Through 
immunohistochemistry, a custom NUCB2/nesfatin-1 antibody (Pacific Immunology, CA, USA) 
confirmed to not cross-react with NUCB1, a homolog to NUCB2, was used to determine the 
localization of the protein in normal and inflamed mouse and human lung samples. Results 
showed that our protein of interest was expressed in the alveolar septa, bronchiolar epithelium, 
vascular endothelium, immune cells and red blood cells in both mouse and human samples. 
Human lung samples revealed that NUCB2/nesfatin-1 was absent in adipose tissues, hyaline 
cartilage and smooth muscle fibers of the tunica media. Further, localization did not change with 
inflammatory status. Afterwards, subcellular localization of NUCB2/nesfatin-1 in mouse lungs 
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was determined through immunoelectron microscopy using the same antibody. Results revealed 
that the protein localized in the cytoplasm and nucleus of pulmonary and immune cells; 
similarly, this did not change with inflammatory status. Lastly, analysis of immunoelectron 
microscopy images of human neutrophils stimulated for 0, 60, 90 and 120 mins with 1 ng/mL 
LPS using a polyclonal NUCB2/nesfatin-3 antibody (NBP1-87383, Novus Biologicals, ON, 
Canada) revealed that the protein accumulated within 0.5 μm of the plasma membrane after 90 
mins of LPS treatment. The protein was consistently present at 5 times the mean concentration in 
the euchromatin compared to heterochromatin portion of the nucleus, and 2 times the mean 
concentration in the cytoplasm compared to nucleus. These observations suggest that 
NUCB2/nesfatin-3 may have a role in transcription regulation, as well as provide important clues 
for potential function and interaction with other molecules. 
 In the second part of our studies, we examine the role of NUCB2/nesfatin-1 in the 
development of ALI using WT and NKO mice stimulated for 9 hours with 50 μL of 1 mg/mL E. 
coli O55:B5 LPS or PBS. Previous animal studies administered nesfatin-1 to rats with 
subarachnoid hemorrhage-induced oxidative brain damage, and traumatic brain injury, and found 
nesfatin-1 to have an anti-inflammatory and anti-apoptotic effect (Ozsavci et al., 2011, Tang et 
al., 2012). Expression of pro-inflammatory cytokines, neutrophil-mediated oxidative damage and 
enzymatic activities, and tissue damage decreased with nesfatin-1 treatment (Ozsavci et al., 
2011, Tang et al., 2012). In our studies, we examined ALI through 3 parameters deemed most 
relevant by the American Thoracic Society: histological evidence of tissue injury, changes in 
alveolar-capillary barrier, inflammatory response and physiological evidence of dysfunction 
(Matute-Bello et al., 2010). Histological analysis through haematoxylin and eosin staining 
revealed no structural damage and no compromise to neutrophil margination in any treatment 
group, but slightly more immune cell accumulation in perivascular and septal spaces of LPS-
treated NKO samples compared to WT. Immunohistochemistry using Gr-1 antibody to identify 
neutrophils for high power magnification counts revealed neutrophil numbers 3 times higher in 
LPS-treated NKO lungs compared to WT. When changes to vascular permeability were 
examined through a protein assay of bronchoalveolar lavage fluid (BALF), results showed no 
significant difference between WT and NKO samples with PBS or LPS treatment. Measures of 
inflammatory response using absolute immune cell and neutrophil counts in BALF revealed no 
significant difference between WT and NKO mice, notably showing that the loss of 
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NUCB2/nesfatin-1 does not affect the non-adherent population of neutrophils following LPS-
treatment. Next, myeloperoxidase activity was used as an indirect measure to quantify adherent 
neutrophil. While there is no significant difference between NKO and WT LPS-treated samples, 
MPO activity in LPS-treated NKO samples was 2.6 times higher than PBS-treated samples, 
whereas the increase was only 1.9 times in WT samples. Lastly, ELISA performed for 23 
inflammatory cytokines in WT and NKO BALF revealed that pro-inflammatory cytokines (TNF-
α and G-CSF), chemokines (MIP-1α and MIP-1β) and a mediator of allergic inflammation (IL-5) 
were significantly upregulated in NKO compared to WT samples. IL-6 expression was also 
upregulated in NKO samples compared to WT, but was slightly short of statistical significance 
(p=0.052); results for IL-1α, IL-1β, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, KC, GM-CSF, 
IFN-γ, RANTES, MCP-1, and eotaxin were not statistically significant; IL-2, IL-3, IL-4 and IL-9 
expression were below detectable levels. While significantly increased cytokine expression of 
TNF-α, MIP-1α and MIP-1β in LPS-treated mouse lungs may, in part, be a result of neutrophil 
accumulation, we must note that these pro-inflammatory cytokines are also expressed by 
macrophages (TNF-α, MIP-1α, MIP-1β) and endothelial cells (TNF-α). Significant differences in 
IL-5 and G-CSF expression between WT and NKO mouse lungs further suggests 
NUCB2/nesfatin-1 to regulate other cell types. While our experiments do not specifically 
investigate other cell types, future studies doing so would provide a more comprehensive picture 
on the role of NUCB2/nesfatin-1 during acute lung inflammation. Peripheral blood analysis was 
performed to determine whether NUCB2/nesfatin-1 had any systemic effect on blood counts; 
results were not statistically significant. Together, these results suggest NUCB2/nesfatin-1 to 
have an anti-inflammatory role, considering that its absence significantly increases adherent 
neutrophil accumulation, and pro-inflammatory cytokine expression in mouse lungs. 
 To more specifically determine the role of mouse neutrophils during acute inflammation, 
we extracted bone marrow neutrophils from WT and NKO mice and stimulated them with 
1ng/mL LPS for 0, 60, 90 and 120mins (5x10
6 
cells per sample; n=3). Culture supernatant was 
analyzed using the same ELISA for 23 cytokines. Results only revealed statistical significance in 
IL-6, where NKO samples expressed 0.4 times the IL-6 of WT samples. Otherwise, only IL-1α, 
TNF-α, RANTES, MIP-1α, MIP-1β, and IL-12(p70) were present at detectable levels, and 
results comparing between WT and NKO samples at different time points were not significant. 
However, the observation that WT samples expresses more cytokines compared to NKO does 
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agree with previous cell culture findings where the addition of nesfatin-1 to chondrocytes after 
inflammatory stimulus increases pro-inflammatory cytokine expression (Scotece et al., 2014). 
Taking into account that neutrophil counts are approximately 3 times in NKO than WT samples, 
the net effect of knocking out NUCB2/nesfatin-1 is still expected to be pro-inflammatory.  
 Lastly, since previous studies have shown inflammatory stimulus to increase 
NUCB2/nesfatin-1 mRNA and protein expression in adipocytes and chondrocytes, we attempted 
to determine if the same occurs in mouse lung tissues and neutrophils (Ramanjaneya et al., 2010; 
Scotece et al., 2014). Protein and mRNA were extracted from WT lung homogenates for LPS 
and PBS-treated samples, and assessed using Western blots and RT-qPCR respectively. Results 
revealed no significant difference in NUCB2/nesfatin-1 protein or mRNA expression for samples 
treated with LPS or PBS. Similarly, protein was extracted from mouse neutrophils that were 
stimulated for 0, 60, 90 and 120 mins, and assessed through Western blots. Again, results 
showed no statistically significant differences. Our results indicate that NUCB2/nesfatin-1 is 
constitutively expressed, and not influenced by LPS stimulation. 
 Taken together, results of our experiments suggest that NUCB2/nesfatin-1 localizes in the 
nucleus and cytoplasm of pulmonary cells as well as immune cells of human and mice; neither 
localization nor expression changes with inflammatory status. In addition, NUCB2/nesfatin-1 
presence in euchromatin and its apparent ability to regulate cytokine expression suggest that it 
may be involved with transcription regulation. The protein appears to exert an anti-inflammatory 
effect by inhibiting adherent neutrophil accumulation and inflammatory cytokine expression. 
Considering that adherent neutrophil accumulation significantly increases in NKO mice whereas 
non-adherent neutrophil counts do not change, NUCB2/nesfatin-1 present throughout the 
epithelium and endothelium of lungs may have a role in inhibiting neutrophil infiltration and 
adhesion during inflammation. This is further supported by lower levels of inflammatory 
cytokines, TNF-α and G-CSF, in WT compared to NKO BALF. These results imply that 
situations which lower levels of circulating NUCB2/nesfatin-1 such as pregnancy or fasting may 
exacerbate neutrophil-mediated conditions such as ALI or COPD; as the population of adherent 
neutrophil increases, resolution time may also increase, impeding recovery from neutrophilic 
inflammation. Future studies should examine whether administration of NUCB2/nesfatin-1 could 
rescue LPS-treated NKO mice from increased pro-inflammatory conditions, or even decrease 
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inflammation at a higher dosage. As an extension of the current study, follow-up experiments 
should also examine more LPS stimulation time points. While our study focused on a 9-hour 
LPS stimulation where inflammation is expected to be at its peak, future studies could extend 
time points to 12 and 24hours to examine the progress of inflammatory resolution. 
 Limitation to our studies include the aforementioned effect of NUCB2/nesfatin-1 on 
cytokine expression of other cell types including macrophages and endothelial cells during acute 
lung inflammation. While they may also significantly contribute to the demonstrated anti-
inflammatory effect of NUCB2/nesfatin-1, our data is insufficient to make this correlation. In a 
future study, inflammatory cytokine expression of WT and NKO macrophages and endothelial 
cells stimulated with LPS should be examined to determine to what extent these cell types 
contribute to the difference of inflammatory cytokine expression observed in LPS-treated WT 
and NKO mouse lungs. The specificity of NUCB2/nesfatin-1 antibodies used in our localization 
study also presents an important limitation. While we can be certain that it detects our protein of 
interest, we cannot rule of the possibility of cross-reaction. Future studies may consider 
engineering a mouse model where NUCB2/nesfatin-1 is tagged with a GFP reporter to eliminate 
this element of uncertainty.   
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APPENDIX I: Quantification of gold particles in immunoelectron microscopy 
images 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.I: Processing image for analysis.  
An image is taken for each randomly chosen neutrophil at 10,000X (top). The image is then adjusted in 
Photoshop CS6; a uniformly-spaced grid is placed on top and the region 0.5 µm inside the plasma 
membrane is highlighted by selecting the cell region with a lasso tool and applying an inner stroke of 
209px (bottom).  
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Figure I.II: Estimating area with grid.  
The cell is divided into 4 regions of interest: 0.5 µm within plasma membrane, remainder of cytoplasm, 
euchromatin (lighter portion of nucleus), and heterochromatin (darker portion of nucleus). The profile 
area of each region is estimated by counting points of intersection. As an example, the above image 
illustrates area counting of 0.5 µm within plasma membrane (blue), remainder of cytoplasm (red) and 
heterochromatin (green).  
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Figure I.III: Counting gold particles.  
Gold particles in each region (PM: 0.5 µm within plasma membrane; Cyt: remainder of cytoplasm; Het: 
heterochromatin; Eu: euchromatin) are quantified accordingly. However, gold particles that are too close 
together (red box) are counted as 1 due to possibility of polyclonal antibodies reacting to different 
epitopes on the same protein. 
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APPENDIX II: Testing for antibody specificity 
II.I NUCB2/nesfatin-1 monoclonal antibody (Custom, Pacific Immunology) 
NUCB2/nesfatin-1 rabbit monoclonal antibody (Custom; Pacific Immunology, CA, USA) 
was developed against a synthetic peptide, VDKTKVHNTEPVENARIEP-Cys (20 AA). The 
sequence is located within nesfatin-1. This antibody was used in localization studies of mouse 
and human lungs during immunohistochemistry and immunoelectron microscopy, as well as all 
Western blot studies conducted within this thesis. In order to confirm its specificity, we 
attempted to create knockout and antigen preabsorption controls. Western blots of mouse lung 
homogenates were also performed. 
Knockout controls were generated using the same immunohistochemistry protocol as 
described in section 2.3.7. NUCB2 KO (NKO) and WT mouse lung tissues were incubated with 
1:50, 1:100, 1:200 and 1:250 dilutions of 1 mg/mL primary antibody. While staining became 
weaker in WT samples with increasing primary antibody dilution, non-specific staining in NKO 
samples remained consistent throughout (Figure II.I). Since nesfatin-1 mRNA was verified to be 
absent in NKO samples through RT-qPCR, it is possible that the antibody is cross-reacting with 
a highly similar compensatory protein.  
Antigen preabsorption controls were generated through incubating synthetic nesfatin-1 
peptide (003-22B; Phoenix Pharmaceuticals, CA, USA) with the antibody at a 2:1 concentration 
overnight. NKO lung tissues were also incubated with the synthetic peptide overnight to block 
off any unoccupied receptors that might bind with synthetic nesfatin-1 in preabsorbed antibodies. 
Tissue sections were briefly washed with PBS afterwards, and preabsorbed antibodies were used 
at a 1:200 dilution. Immunohistochemistry was carried out without further changes. Results 
showed non-specific staining for epithelial and endothelial layers relatively uniform in strength 
(Figure II.II). 
Western blots were also performed on WT and NKO lung homogenates to determine 
antibody specificity. ENCODE guidelines (2011) suggest using a combination of 
characterization methods. In order to meet requirements of specificity using immunoblot 
analyses, the protein of interest, NUCB2/nesfatin-1, must be detected with a signal larger than 
50% the total signal. Figure II.III shows that the majority of signal in all samples are at ~55kDa, 
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representing the molecular weight of NUCB2. Further, ENCODE guidelines (2011) suggest a 
sufficiently specific antibody should detect no more than 30% of the WT signal in KO samples. 
Densitometry was performed for the NUCB2 bands identified at ~55 kDa, revealing that all but 2 
WT signals were >30% of the NKO signal. This presents reasonable evidence for antibody 
specificity; however, we cannot completely rule out the presence of cross-reaction.  
During the course of antibody testing, a commercial NUCB2/nesfatin-1 polyclonal 
antibody from Phoenix Pharmaceuticals, CA, USA (H-003-22) was also examined. Results 
produced were similar, but the antibody is known to react with NUCB1 and Western blot results 
have shown a slightly higher degree of non-specificity with more bands than one at ~55 kDa 
detected (data not shown). 
II.II NUCB2/nesfatin-3 polyclonal antibody (NBP1-87383, Novus Biologicals) 
NUCB2/nesfatin-3 rabbit polyclonal antibody (NBP1-87383; Novus Biologicals, ON, 
Canada) was developed against a recombinant protein with the sequence of a segment within 
nesfatin-3. In order to confirm the specificity of the antibody to be used in immunoelectron 
microscopy of human neutrophils, Western blots were performed on mouse lung and pancreas 
homogenates, and human neutrophils. Non-specific binding was blocked with 5% BSA in TBS 
containing 0.1% Tween 20 (TBS-T) for 1hour at RT. The membrane was then incubated with the 
aforementioned NUCB2 antibody diluted 1:500 in TBS-T with 3% BSA overnight at 4°C. 
Afterwards, the membrane was washed with TBS-T and incubated with anti-rabbit Alexa Fluor® 
488 (A-11008, Thermo Fisher Scientific, MA, USA) for 1 hour at RT and visualized on the GE 
Healthcare Typhoon 9400 imager.  Adequate specificity of the primary antibody was evaluated 
according to ENCODE guidelines (ENCODE, 2011). β-actin was used as the reference gene for 
normalization.  
According to ENCODE guidelines (2011) the protein of interest, NUCB2/nesfatin-3, 
must be detected with a signal larger than 50% the total signal. Figure II.IVA shows the antibody 
reacting against human neutrophil homogenates with signals at ~50 kDa and ~10 kDa, of which 
the signal at ~50 kDa represents NUCB2. Densitometry performed shows that all NUCB2 
signals ~50 kDa were at least twice of that at ~10 kDa. A secondary mode of characterization 
was performed to compare signals between WT and NKO tissues with the principle that a 
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sufficiently specific antibody should detect no more than 30% of the WT signal in KO samples. 
While Figure II.IVB shows an immunoblot detecting vast amounts of non-specificity associated 
with lung and pancreas tissue, these were not detected in human neutrophil homogenates. 
Densitometry was performed for the NUCB2 band identified at ~55 kDa. Results showed a band 
in pancreas from NKO mice with 5% the WT signal, while the band in lung samples from NKO 
mice had 10% the weakest (lane 3) and 6% strongest (lane 4) WT band signal.   
Altogether, results show that although the possibility of cross-reaction is not completely 
eliminated, the chosen polyclonal anti-NUCB2/nesfatin-3 antibody (NBP1-87383; Novus 
Biologicals, ON, Canada) has sufficient specificity for detecting NUCB2/nesfatin-3 in human 
neutrophils. Aside from this, one of the main reasons for this antibody choice was its ability to 
achieve a quantifiable amount of immunogold staining during IEM; the chosen anti-NUCB2 
polyclonal antibody (NBP1-87383; Novus Biologicals, ON, Canada) out-performs monoclonal 
anti-NUCB2 antibodies (Custom; Pacific Immunology, CA, USA) (data not shown). 
104 
  
Figure II.I: Immunohistochemistry of WT and NKO mouse lungs.  
Immunohistochemistry performed using NUCB2/nesfatin-1 rabbit monoclonal antibody (Custom, Pacific 
Immunology) on WT and NUCB2 KO mouse lungs at 1:50, 1:100, 1:200 and 1:250 dilution.  
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Figure II.II Immunohistochemistry of NKO mouse lungs with preabsorbed antibody. 
Immunohistochemistry was performed with rabbit monoclonal NUCB2/nesfatin-1 antibody (Custom, 
Pacific Immunology) preabsorbed using synthetic nesfatin-1 peptide (003-22B, Phoenix Pharmaceuticals) 
at 1:200 dilution on NKO mouse lungs previously incubated with the same synthetic nesfatin-1 peptide.  
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Figure II.III: Western blot analysis of anti-NUCB2/nesfatin-1 antibody specificity.  
Western blot specificity testing of anti-NUCB2 antibody/nesfatin-1 (Custom, Pacific Immunology) using 
protein from lung homogenates of WT LPS (lane 1-3) and PBS-treated (lane 5-7) mice, and NKO (lane 8) 
mouse. A protein ladder was run on lane 4. Band specific for NUCB2 can be identified ~55kDa. 
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Figure II.IV: Western blot analysis of anti-NUCB2/nesfatin-3 antibody specificity.  
Western blot specificity testing of anti-NUCB2/nesfatin-3 antibody (NBP1-87383, Novus Biologicals) 
using (A) protein from human neutrophil (lane 2-5; n=4), and (B) WT (lane 2-5; n=4) and NKO (lane 7) 
mouse lung homogenates, NKO (lane 8) and WT (lane 9) mouse pancreas homogenates. Protein ladders 
were loaded in lanes 1 and 6 of both blots. 
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APPENDIX III: Pilot Experiments 
Two pilot experiments were carried out during the course of all NUCB/nesfatin-1 
characterization studies. The first was initiated upon observation of NUCB2/nesfatin-1 presence 
in euchromtic portions of human neutrophils through IEM. Its primary objective was to 
determine potential DNA-binding motifs, establish a genome-wide binding profile and assess 
binding affinity. An attempt at chromatin immunoprecipitation-sequencing (ChIP-sequencing) 
was carried out using unstimulated human neutrophils (n=2) to immunoprecipitate chromatin 
fragments associated with NUCB2/nesfatin-1 within the nuclei. The pilot would allow practice 
and refinement of a pre-existing protocol developed by Dr. Richard Myers’ Lab at the Hudson 
Alpha Institute for Biotechnology (Myers Lab, 2014). Specifically optimizing it to process 
human neutrophils using the VC300 VibraCell sonicator, and ultimately isolate sufficient 
chromatin fragments for sequencing.  
Another pilot study was carried out to examine the distribution patterns of 
NUCB2/nesfatin-1 in WT mouse neutrophils following LPS stimulation through confocal 
microscopy. The objective was to practice the protocol which would ultimately provide reliable 
results through a secondary method to support IEM findings in human neutrophils.   
III.I Chromatin immunoprecipitation for sequencing 
 Human blood was collected from healthy volunteers and neutrophils were isolated as 
described above. All buffers were made according to the Myers lab protocol; 2x10
7 
untreated 
neutrophils were used as starting material. Chromatin-protein and protein-protein cross-links 
were formed by adding formaldehyde to the final concentration of 1% and incubating at RT for 
10 mins. The reaction was stopped by adding glycine to the final concentration of 0.125 M. Cells 
were then washed with PBS, resuspended in 1 mL Farnham lysis buffer and incubated on ice for 
15 mins. Lysate was then passed through a 20-gauge needle 20 times to facilitate extraction of 
intact nuclei from the cells. Nuclei were then resuspended in 1mL RIPA buffer (300 µL and 1.2 
mL RIPA buffer volumes were tested according to protocol but resulting fragments were too 
large or too small) and sonicated with the VC300 VibraCell sonicator (630-0418 tapered tip) to 
produce chromatin fragments. Each cycle of sonication consisted of 30 secs ON (pulser off; 
output control at 5) and 1 min OFF where samples were left on ice. 5 cycling conditions (2, 4, 6, 
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8, 10 cycles) were examined to determine optimal conditions where fragments would enrich 
around 100-500 bp and centre around at 250 bp with the least amount of cycles. As shown in 
Figure III.I, 6 cycles in 1 mL RIPA buffer produced optimal results. Small aliquots of 
fragmented chromatin were set aside in -80°C as input control for each successfully sonicated 
sample while the rest proceeded to downstream immunoprecipitation. 
 Dynabeads™ M-280 Sheep Anti-rabbit IgG (11203D; Invitrogen, CA, USA) was 
incubated with 5 µg custom anti-NUCB2 antibody (Pacific Immunology, CA, USA) overnight 
for conjugation. Afterwards the beads were washed with 5% BSA with protease inhibitor 
cocktail and incubated with fragmented neutrophil chromatin overnight at 4°C. The final product 
was washed 5 times in LiCl, once in TE buffer using a magnet and resuspended in IP elution 
buffer.  
Lastly, cross-links with proteins were reversed to extract immune-bound chromatin from 
magnetic beads by incubating at a 65°C water bath for 1 hour. Beads were separated through 
centrifugation, the supernatant was collected and incubated at a 65°C water bath overnight to 
complete cross-link reversal. The QIAquick PCR Purification Kit (28104, Qiagen) was used to 
elute DNA and the Qubit™ dsDNA HS Assay Kit was used to evaluate DNA yield. Expected 
DNA recovery in a successful immunoprecipitation is 5-50 ng from 2x10
7 
cells as starting 
material. This was achieved in both final samples (6 and 7 ng) sent for sequencing library 
construction. An attempt was made to accommodate for low yield, however library construction 
was ultimately unsuccessful.        
 This portion was discontinued due to insufficient DNA recovery for ChIP-seq library 
construction and time constraints. Low recovery may be the result of nuclear NUCB2/nesfatin-1 
being obscured by cytoplasmic NUCB2/nesfatin-1. Future trials to optimize this protocol could 
consider adding a wash step after Farnham buffer lysis of plasma membranes; however, this 
poses a risk of diluting the chromatin. Other options would be to first find conditions where 
NUCB2/nesfatin-1 is up-regulated in nuclei, or to pool 2 or more samples from the same 
biological source.     
III.II Confocal microscopy of LPS-stimulated mouse neutrophils 
 Bone marrow neutrophils were extracted from 2 WT (C57BL/6J), and 2 PBS-treated WT 
(C57BL/6NCRL) mice and samples from each pair were pooled. Six well plates were set up to 
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contain neutrophils at 2x10
6 
cells/mL. Placed at the centre, each well also had an etched glass 
coverslip that was pre-coated with 20 µL 1mg/mL fibronectin for 45 mins. Cells were stimulated 
with 1 ng/mL LPS (L2880, Sigma-Aldrich) for 0, 60, 90 and 120 mins respectively, and 
incubated at 37°C with 5% CO2. After stimulation, glass coverslips were taken from the wells, 
washed in PBS and fixed with 4% paraformaldehyde/0.1% TritonX-100 for 2 mins at RT. Cells 
were then blocked with 5% BSA at RT for 30 mins then incubated with 1:200 rabbit NUCB2 
antibody (Custom, Pacific Immunology) at 4°C overnight. The next day, coverslips were 
incubated with a cocktail of fluorescent antibodies. During the first trial (WT C57BL/6J mice), 
cells were incubated with goat anti-rabbit IgG-FITC (sc-2012; Santa Cruz Biotechnology, TX, 
USA) and Alexa Fluor® 555 phalloidin (A34055, Life Technologies); during the second trial 
(WT C57BL/6NCRL), cells were incubated with goat anti-rabbit Alexa Fluor® 633 (A-21070, 
Life Technologies, CA, USA) and Alexa Fluor® 488 phalloidin (A12379; Life Technologies, 
CA, USA). Coverslips were then incubated with 1:10000 DAPI (D3571, Life Technologies) for 
5mins in RT and mounted onto microscope slides using ProLong™ Gold Antifade Mountant 
(P36934, Thermo Fisher Scientific). Slides were left to dry in the dark overnight before storing 
into a slide box until confocal microscopy. 
 During the first trial, wash steps may have lasted too long as many neutrophils became 
washed off; glass coverslips may have also been insufficiently etched. However, an image of 
NETs was obtained from a sample treated with LPS for 120 mins (Figure III.II), suggesting that 
NUCB2/nesfatin-1 may be released along with chromatin DNA to form extracellular traps. 
During the second trial, there were no observations of NETs. Instead, a distinct NUCB/nesfatin-1 
distribution pattern was observed where the protein in unstimulated cells was mostly diffuse, and 
became concentrated towards the plasma membrane as time exposed to LPS increased (Figure 
III.III). These preliminary results supported observations in human neutrophils seen in IEM 
where immunostaining shifts towards the plasma membrane after 90 mins LPS stimulation. 
However, the experiment was not pursued as negative controls did not validate the protocol used. 
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Figure III.I: Gel electrophoresis of human chromatin fragmentation after sonication.  
Human neutrophil chromatin was fragmented using the VC300 VibraCell sonicator where each cycle 
consists of 30 secs ON, 1 min OFF (on ice). The above samples were sonicated for 2, 4, 6, 8, and 10 
cycles respectively with 6 being the least amount of cycles needed to result in optimal fragmentation 
distribution (100-500bp spread).
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Figure III.II: Confocal image of NUCB2/nesfatin-1 in neutrophil extracellular traps after 120mins 
1ng/mL LPS stimulation.  
A composite maximum intensity projection (MIP) image was created from a series of z stacks to show 
NETs and 3 surrounding neutrophils almost devoid of chromatin DNA. (Blue: DAPI, Red: β-actin, Green: 
NUCB2/nesfatin-1)   
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Figure III.III: NUCB2/nesfatin-1 distribution following LPS treatment.  
Neutrophils from C57BL/6J WT mice were isolated and challenged with 1 ng/mL LPS for 0, 60, 90, and 
120 mins. Neutrophils shown are single plane images representative of 1 biological replicate.  
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